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ABSTRACT
Cognitive function represents the most important determinative factor for
independent functioning in the elderly. As the existing pharmacotherapeutic tactics for
treating Alzheimer’s disease (AD) provide only modest benefits, novel treatment options
are urgently needed. The hypothalamic orexin (hypocretin) system, a central integrator of
physiological function, is anatomically and functionally positioned to modulate
cognition. Indeed, mounting evidence suggests that a loss of orexin neurons and/or their
peptides and receptors may underlie the cognitive decline observed during aging and AD.
The current paucity of orexin receptor agonists has hindered the ability to study their
potential as cognitive enhancers. Intranasal administration of orexin peptides circumvents
these issues and others involving peptide delivery into the CNS. To investigate the
overarching hypothesis that intranasal orexin administration improves the anatomical,
neurochemical, and behavioral substrates of age-related cognitive dysfunction, the
proceeding studies utilized a rodent model of aging in combination with acute intranasal
administration of saline, orexin-A or the modified orexin-B analog [Ala11, D-Leu15]orexin-B. These results highlight that intranasal OxA (5nmol) increases c-Fos expression,
a marker for neuronal activation, in various telencephalic brain regions, including various
subdivisions of the frontal cortex and the basal forebrain cholinergic system. Importantly,
these brain regions are known to modulate attention and learning and memory in both
young and aged subjects. Conversely, administration of intranasal [Ala11, D-Leu15]orexin-B (5nmol), an orexin-2 receptor (Ox2R) selective peptide, elicited increases in c-
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Fos expression that were far less reaching, suggesting that the orexin-1 receptor may
provide a more important mechanistic role in this context. To ensure that intranasal
orexin administration was affecting neurotransmission in-vivo, a separate cohort of
animals were utilized for a prefrontal cortex (PFC) in-vivo microdialysis study, where
counterbalanced animals received both intranasal saline and intranasal orexin-A over two
separate sessions. Acetylcholine and glutamate in PFC dialysates were measured by highperformance liquid chromatography. These results show that intranasal orexin-A
increases PFC acetylcholine and glutamate efflux, two putative neurochemical correlates
of attentional function, in young and aged rats. Importantly, deficits in in-vivo cholinergic
and glutamatergic neurotransmission play an essential role in the attentional dysfunction
observed during aging. Therefore, to test whether intranasal orexin-A administration
improves attentional capacity, a separate cohort of animals were trained and tested in an
attentional set-shifting (ASST) behavioral paradigm. These results show that vehicletreated aged animals are impaired in the extradimensional shift (EDS) stage compared to
vehicle-treated young animals, highlighting that aging impairs PFC-mediated attentional
function. Importantly, intranasal orexin-A in aged animals abolished the age-related EDS
impairment relative to young control animals treated with saline. These results indicate
that intranasal orexin-A may restore age-related PFC dysfunction to levels on par with
their cognitively intact younger counterparts. Together, these studies highlight the
putative mechanisms that underlie cognitive dysfunction during aging and provide
insights into the possible therapeutic benefit of intranasal orexin-A in treating age-related
cognitive dysfunction.
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CHAPTER 1
GENERAL INTRODUCTION
1.1: Significance
Cognitive impairment is a core feature of several neuropsychiatric and neurological
disorders, including narcolepsy and age-related dementias. Demographic trends indicate an
aging American populace; therefore, rates of age-related neurodegenerative diseases,
including Alzheimer’s disease (AD), are projected to increase significantly over the next
several decades. While a plethora of approaches are currently being investigated to solve
these disorders, it is of paramount importance that novel diagnostics, strategies, and therapies
are developed to combat these devastating diseases. Current pharmacotherapeutic options for
cognitive enhancement are scarce and limited in efficacy. Thus, novel treatment strategies are
needed. The hypothalamic orexin (hypocretin) system, a central integrator of physiological
function, plays an important role in modulating cognition. Several single- and dual-orexin
receptor antagonists are available for various clinical and preclinical applications, but the
paucity of orexin agonists has limited the ability to research their therapeutic potential. To
circumvent this hurdle, direct intranasal administration of orexin peptides is being
investigated as a prospective treatment for cognitive dysfunction, narcolepsy, or other
disorders in which deficient orexin signaling has been implicated. The studies were designed
to elucidate the possible mechanisms and therapeutic potential of intranasal orexin delivery.
The results from these neurochemical and behavioral studies in young and aged animals
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highlight the capacity for intranasal orexin administration to improve age-related deficits in
neurotransmission and provide a potential framework for the use of intranasal orexin peptides
in treating age-related cognitive dysfunction.
1.2: Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disease that affects
approximately 6 million Americans. The disease is currently the 6th leading cause of
death in the United States with an estimated cost burden of 290 billion dollars in 2019
alone. Because of advances in other areas of medicine, life expectancy across the globe
has risen and, therefore, cases of late-onset AD are expected to rise to 14 million by the
year 2050 (Alzheimer’s Association, 2019). Indeed, by definition, the largest risk factor
for developing late-onset AD is age (Hebert et al. 1995).
The origins of AD date back to the early 20th century when German psychiatrist
and neuropathologist Alois Alzheimer identified plaques and neurofibrillary tangles in a
recently deceased patient that had been suffering from memory loss and hallucinations
(Cipriani et al. 2011). While AD exists in both the early-onset and late-onset forms, the
latter is much more common and its etiology far less understood. The primary
pathological hallmarks of AD, amyloid-β plaques and hyperphosphorylated-tau in
neurofibrillary tangles, gradually accumulate over the course of the disease with
devastating effects to synapses and neurons. Thus, one of the main avenues of research in
recent years has been in developing therapies for disrupting or preventing amyloid-β and
hyperphosphorylated-tau pathologies. Unfortunately, none of the amyloid-β targeting
therapies have passed phase 3 clinical trials due to lack of statistical significance on pre-
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clinically defined endpoints. Even more concerning for this therapeutic route is that while
these amyloid targeting therapies are efficacious in removing plaques, they are not
efficacious at slowing disease progression (Selkoe and Hardy 2016; Scheltens et al.
2016). These concerns point to the complexity of AD and, unfortunately, suggest a
probable need for individualized therapies and/or a combination of treatments.
1.3: Cholinergic receptors and neurotransmission
Acetylcholine is one of the major neurotransmitter in the brain with wide reaching
activity and effects on cognition (Francis et al. 1999; Everitt and Robbins 1997; Mesulam
2013; Schliebs and Arendt 2011). Acetylcholine is synthesized within the presynaptic
nerve terminals of cholinergic neurons by the enzyme choline acetyltransferase (ChAT).
This enzyme uses acetyl CoA, a byproduct of glucose breakdown in the Krebs cycle,
along with the main substrate choline to synthesize the neurotransmitter acetylcholine.
Acetylcholine is then packaged into vesicles by the vesicular acetylcholine transporter
(vAChT) where it is stored until its release during neurotransmission. After release into
the synapse, acetylcholine will bind to specific post-synaptic receptors (M1 muscarinic
receptors) in order to propagate a cholinergic signal from neuron to neuron. Within the
synaptic cleft, acetylcholine is degraded by the enzyme acetylcholinesterase (AChE) into
choline and acetate, which are ultimately taken back into nerve terminals and recycled for
further production of acetylcholine (Tucek 1990). Once acetylcholine is released from the
presynaptic terminal, it binds to two classes of receptors: nicotinic acetylcholine receptors
(nAChR) and muscarinic acetylcholine receptors (mAChR). Nicotinic acetylcholine
receptors are ligand-gated ion channels composed of five different subunits: two alpha
subunits, one beta subunit, one gamma subunit, and one delta subunit. The nicotinic
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receptors are primarily classified into two separate groups: heterometric receptors and
homomeric receptors. The heteromeric receptors are primarily composed of two different
types of subunits (Karlin and Akabas 1995; Taly et al. 2009). Among the heteromeric
receptors, the α4β2 subtype is the most predominant receptor in the CNS. The homomeric
receptors are composed of five identical subunits and is mainly represented by the α7
subtype within the CNS. Nicotinic acetylcholine receptors within the CNS can be located
on somata, dendrites, axons, or axon terminals. Presynaptic and preterminal nAChRs
enhance neurotransmitter release while postsynaptic nAChRs activate intracellular
signaling mechanisms and gene transcription (McKay et al. 2007; Dani and Bertrand
2006). Acetylcholine also signals through metabotropic muscarinic receptors (mAChRs),
which are G-coupled protein receptors coupled to either Gi or Gq. The M1, M3, and M5
subtypes are excitatory and are coupled to Gq and the M2 and M4 subtypes are inhibitory
and are coupled to Gi (Felder 2018). The M1 receptor subtype is expressed
postsynaptically and increases neuronal excitability. The M2 and M4 receptor subtypes
represent the major presynaptic mAChRs in the brain and function to suppress
cholinergic and glutamatergic neurotransmission. M2 can also be expressed
presynaptically at GABAergic terminals. The M3 and M5 subtypes are expressed at
lower levels in the brain, but function in a manner similar to M1 mAChRs (Lebois et al.
2018).
Cholinergic neurons function as interneurons or as projections neurons.
Cholinergic interneurons of the striatum provide dense local innervation and function in
sensorimotor planning and learning (Zhou et al. 2002). Cholinergic neurons of the
pedunculopontine nucleus (PPT) and laterodorsal tegmentum (LDT) function as
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regulators of REM sleep during the natural sleep/wake cycle (Dort et al. 2015). The
primary source of cholinergic innervation to the neocortex is provided by cholinergic
neurons within the basal forebrain. The basal forebrain cholinergic system (BFCS) is
divided into four subdivisions (Ch.1-4). The medial septum (Ch.1) provides dense
innervation to the hippocampus. The vertical limb of the diagonal band (Ch.2) provides a
major source of innervation to the hippocampus and hypothalamus. The horizontal limb
of the diagonal band (Ch.3) provides dense innervation of the olfactory bulb. Finally, the
contiguous nucleus basalis/ventral pallidum/substantia innominata (Ch.4), sends
widespread projections to the amygdala and neocortical areas like the prefrontal cortex,
insular cortex, and posterior parietal cortex (Mesulam et al. 1983a).
1.3.1: The cholinergic hypothesis of Alzheimer’s disease
The original hypothesis of AD was driven from studies noting cholinergic
dysfunction during the disease: The first observation was a reduction of presynaptic
cholinergic markers in the cortex of AD patients (Bowen et al. 1976; Davies and
Maloney 1976). It was also discovered that the nucleus basalis degenerates during the
disease (Mesulam 1976; Whitehouse et al. 1981). Finally, research into the effects of
cholinergic agents on memory showed that cholinergic antagonists impair memory and
cholinergic agonists improve memory (Drachman and Leavitt 1974). This hypothesis,
although flawed in some ways, has validity as the primary therapeutics used to treat AD
are cholinesterase inhibitors. Of the current FDA approved treatments for AD, 4 are
acetylcholinesterase inhibitors that act by inhibiting the enzymatic breakdown of
acetylcholine in the synaptic cleft. These treatments are approved for the treatment of
mild to moderate AD. The only other FDA approved treatment for AD is memantine, an
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NMDA receptor antagonist, which is approved alone or in combination with
cholinesterase inhibitors for the treatment of moderate to severe AD. Unfortunately,
neither class of drug is efficacious at halting progress of the disease, with most of the
cognitive benefits occurring during the early phases of treatment (Yiannopoulou and
Papageorgiou 2013; Lleó et al. 2005). Nonetheless, the progressive loss of basal
forebrain cholinergic neurons and the ensuing degradation of afferents to the cortex,
hippocampus, and amygdala represent a critical component of AD etiology (Cavedo et al.
2018; Sassin et al. 2000).
1.4: The hypothalamus
The hypothalamus, a diencephalic brain region, is the primary central nervous
system locus for coordinating endocrine, autonomic, and behavioral responses to
peripheral cues indicative of homeostatic status. The lateral hypothalamus (LH),
originally defined as the ‘feeding center’ (Willie et al. 2002; Shimada et al. 1998; Sakurai
et al. 1998), has abundant efferent and afferent connections to various brain regions,
suggesting that the LH is highly involved in functions outside of feeding behavior.
Indeed, lesioning studies indicate that the LH plays a crucial role in facilitating arousal
(Lin et al. 1989; Swett and Hobson 1968; Robinson and Wishaw 1974; Jones 2003).
Proper homeostatic and cognitive functioning in the elderly are extremely important
factors for determining independent functioning in the elderly. In the elderly human
population, physiological and homeostatic dysfunction, especially unexplained weight
loss, may be key determinants for predicting cognitive decline into AD (Grundman 2005;
Johnson et al. 2006; Cova et al. 2016; Buchman et al. 2005). This rapid, unexplained
weight loss may represent an important clinical correlate of hypothalamic dysfunction in
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the elderly. Although the mammalian hypothalamus contains a divergent array of nuclei
and neural signaling molecules, the orexin (hypocretin) system plays a particularly
prominent role in homeostatic regulation.
1.5: The orexin/hypocretin system
Two decades have passed since the discovery of the orexin/hypocretin (hereafter
referred to as orexin) system by two separate laboratories in 1998. One group named the
newly discovered pair of peptides hypocretin-1/hypocretin-2 due to their exclusive
expression in the postero-lateral hypothalamus/perifornical area (de Lecea et al. 1998),
while the other group named the pair of peptides orexin-A/orexin-B (OxA/OxB) after the
Latin word ‘orexis’ meaning appetite (Sakurai et al. 1998). The gene that codes for
orexin is structurally conserved among vertebrates and is comprised of two exons and
one intron. Human orexin mRNA is composed of 616 bases which encodes the 131
amino acid prepro-orexin peptide. The prepro-orexin peptide ultimately serves as the
precursor for the OxA and OxB peptide isoforms (Bai et al. 2018). Orexin-A contains 33
amino acid residues and orexin-B contains 28 amino acid residues, with the two peptides
sharing a sequence homology of 46% (Sakurai et al. 1998; Alvarez and Sutcliffe 2002).
During their original discovery, the orexin peptides were found to be endogenous ligands
for two G-protein coupled receptors, the orexin-1/hypocretin-1 receptor and the orexin2/hypocretin-2 receptor. The OxA peptide binds to the orexin-1 and orexin-2 receptors
with approximately equal affinity, while the orexin-B peptide possesses a higher affinity
for the OX2 receptor (Smart and Jerman 2002; Ammoun et al. 2003; Gotter et al. 2012a;
Leonard and Kukkonen 2014). Orexin neurons are glutamatergic (Rosin et al. 2003;
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Torrealba et al. 2003) but also colocalize several other substances including dynorphin
and neurotensin (Chou et al. 2001; Furutani et al. 2013).
1.5.1: Functional modulation of orexins
The orexin system originates with neurons largely restricted to a posterior
hypothalamic level that includes the lateral hypothalamus, perifornical area, and parts of
the dorsomedial nucleus, but gives rise to widespread projections that regulate limbic,
cortical, and brain stem circuits (Peyron et al. 1998). Furthermore, orexin neurons receive
reciprocal afferents, largely from limbic regions (Sakurai 2005; Yoshida et al. 2006).
This diverse array of connections is consistent with the description of orexins as
‘physiological integrators’(Li et al. 2014), but also suggests that orexins have the
potential to modulate cognition. Furthermore, expression of orexin receptor mRNA is
observed widely across the brain, with each receptor showing varied expression across
the central nervous system (Marcus et al. 2001; Trivedi et al. 1998; Hervieu et al. 2001).
Together, this heterogeneous collection of neural circuits suggests that orexin neurons
have a distinct capacity to regulate endocrine, autonomic, and behavioral responses in
order to maintain homeostasis (Li et al. 2014).
The extensive connectome of the hypothalamic orexin system puts it in a prime
position to activate a multitude of phenotypic neurons throughout the brain. Indeed,
orexin neuropeptides have been shown to excite neurons in a plethora of brain regions
including GABAergic neurons in the medial septum, pyramidal neurons in the prefrontal
cortex, and cholinergic neurons of the basal forebrain and laterodorsal tegmentum (Wu et
al. 2002; Yan et al. 2012; Eggermann et al. 2001; Arrigoni et al. 2010; Burlet et al.
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2018). Interestingly, recent work has demonstrated that orexin neurons are excited
directly through the orexin-2 receptor and indirectly from orexin peptide excitation of
glutamatergic neurons that synapse onto orexin neurons (Li et al. 2002; Yamanaka et al.
2010). Electrophysiological studies have also demonstrated that various neurotransmitters
and neuropeptides can influence the activity of orexin neurons through direct and indirect
pathways. For example, orexin neurons are depolarized in the presence of glutamatergic
agonists for either the AMPA or NMDA receptor while antagonists for these receptors
inhibit orexin neuron activity (Li et al. 2002). Furthermore, orexin neurons are
hyperpolarized in the presence of agonists for the GABAA or the GABAB receptor (Xie et
al. 2006; Li et al. 2002). Interestingly, application of antagonists for the AMPA, NMDA,
and GABAA receptors blocked all synaptic events from orexin neurons, suggesting that
glutamate and GABA are the primary sources of input to orexin neurons (Li et al. 2002).
Furthermore, catecholamines appear to inhibit the activity of orexin neurons both directly
and indirectly via modulation of GABAergic and glutamatergic input onto these neurons
(Li et al. 2002; Yamanaka et al. 2003; Li 2005).
1.5.2: Orexin regulation of sleep/wakefulness
The importance of the orexin system in regulating sleep and wakefulness becomes
evident in the neurological disorder, narcolepsy. Of the many responsibilities that the
orexin system carries, its involvement in promoting wakefulness is arguably the clearest
observable phenomenon. Now recognized as a specific loss of orexin neurons and a
subsequent deficiency in orexin peptides (Burgess and Scammell 2012; Thannickal et al.
2000; Nishino et al. 2000), human narcolepsy is diagnosed in patients that present with
diminished alertness, chronic daytime sleepiness, and, depending upon the narcoleptic
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subtype, possible cataplexy, sleep paralysis, and hypnagogic hallucinations. The shortage
of orexin transmission in narcoleptic symptomatology highlights the important role of
orexin neurons in regulating sleep/wakefulness and their ability to inhibit spontaneous
transitions into REM sleep. Indeed, during non-pathological conditions, orexin neurons
are at peak activity during periods of wakefulness and show little to no activity during
both REM and non-REM sleep (Lee 2005; Mileykovskiy et al. 2005; Ferrari et al. 2018).
Furthermore, orexin overexpression in zebrafish induces a hyperlocomotive state and an
phenotype that parallels states of insomnia (Sung et al. 2006). Recent mechanistic
investigations have also revealed that orexin deficiencies result in deficits in thetadominated wakefulness, a neural oscillation pattern that associated with goal-driven
behaviors (Tyree et al. 2018; Vassalli and Franken 2017).
1.5.3: Orexins modulate cognitive function
While the orexin system is chiefly labeled as a ‘physiological integrator’,
mounting evidence suggests that orexins may also modulate cognitive functions including
attention, wakefulness/arousal, and learning and memory. Orexin modulation of cognitive
function arises from multifarious interactions within telencephalic and hindbrain regions
and their neurotransmitter systems. For example, orexins can modulate attentional
function through connections with dopaminergic and noradrenergic systems of the ventral
midbrain and locus coeruleus, respectively (Fadel and Deutch 2002; Horvath et al. 1999;
Baldo et al. 2003; España et al. 2005; Vittoz and Berridge 2006). Furthermore, orexins
can also facilitate attentional function through excitation of basal forebrain cholinergic
neurons (Fadel and Burk 2010; Zajo et al. 2016) and modulation of glutamatergic
thalamocortical synapses (Huang et al. 2006; Lambe et al. 2005; Song et al. 2006) that
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ultimately alter prefrontal cortical release of acetylcholine and glutamate. Importantly,
orexin-mediated effects on cognition are not limited to attention as OxA has also been
shown to alter long-term synaptic plasticity, a presumed correlate of learning and
memory, through coordinated alterations of cholinergic, glutamatergic, GABAergic, and
noradrenergic transmission within the hippocampus (Selbach et al. 2004; Selbach et al.
2010; Yang et al. 2014). Indeed, the powerful effect of orexins on synaptic plasticity
may underlie their role in persisting behavioral adaptations in a variety of contexts
(Baimel and Borgland 2017; Borgland et al. 2006).
1.5.4: Orexin modulation of the basal forebrain
The basal forebrain is a highly complex subcortical brain region composed of
series of heterogeneous subdivisions which include the medial septum (Ch.1), the vertical
limb of the diagonal band of Broca (Ch.2), the horizontal limb of the diagonal band of
Broca (Ch.3), and the ventral pallidum/ substantia innominata/ nucleus basalis (Ch.4)
(Mesulam et al. 1983b). The subdivisions of the basal forebrain contain cholinergic,
GABAergic, and glutamatergic neurons, with cholinergic and GABAergic neurons
constituting the majority of the neurons present (Hur and Zaborszky 2005; Zaborszky et
al. 1999; Gritti et al. 2003). Prior to the discovery of the orexin system, anterograde
tracing studies demonstrated that projections originating from the lateral hypothalamic
area, the putative location of orexin neurons, were observed to innervate basal forebrain
cholinergic neurons (Cullinan and Záborszky 1991). Future tracing studies later
confirmed that orexin immunoreactive fibers originating from the lateral hypothalamic
area do indeed provide dense innervation to the basal forebrain (Peyron et al. 1998; Date
et al. 1999). Moreover, orexin inputs to putative postsynaptic targets in the basal
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forebrain have also been characterized. Specifically, appositions from orexin
immunoreactive fibers have been observed on cholinergic-positive and parvalbuminpositive GABAergic cells in the ventral pallidum/substantia innominata, suggesting that
these neurons of the basal forebrain are post-synaptic targets of orexin neurons (Fadel et
al. 2005; Fadel and Burk 2010). Indeed, orexins directly modulate basal forebrain
activity. For one, behavioral and electrophysiological evidence indicates that activation of
basal forebrain PV+ GABAergic neurons is facilitated through the orexin-2 receptor
(Mieda et al. 2011; Wu et al. 2002). Furthermore, in-vitro evidence suggests that OxA
and orexin-B are approximately equipotent in exciting basal forebrain cholinergic
neurons, suggesting that cholinergic activation is mediated primarily via the orexin-2
receptor (Eggermann et al. 2001). Other studies also point to the orexin-1 receptor having
a crucial role in modulating the basal forebrain function, particularly functions involved
in wakefulness. For instance, intrabasalis administration of OxA elicits a greater response
on somatosensory cortical acetylcholine release than does OxB (Dong et al. 2006).
Furthermore, the orexin-1 receptor antagonist SB-334867 abolishes stimulated
acetylcholine release during feeding (Frederick-Duus et al. 2007). Ultimately, the orexin1 and orexin-2 receptors may indeed play distinct and/or synergistic functional roles in
modulating the basal forebrain cholinergic system in addition to other phenotypic
neurons of the basal forebrain.
1.5.5: Orexin-neurotransmitter interactions: focus on attentional modulation
The studies mentioned herein primarily focus on the interactions between the
orexin system and the neurotransmitters acetylcholine, glutamate, and GABA as they
relate to cognitive function, especially attention. A substantial volume of evidence has
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demonstrated clear orexin-cholinergic interactions and their potential role in modulating
attentional function. A small and unstable neurotransmitter, acetylcholine is synthesized
in presynaptic terminals of cholinergic neurons by the enzyme choline acetyltransferase
(ChAT), a selective marker for cholinergic neurons in the brain. In addition to the basal
forebrain, the primary source of acetylcholine for the neocortex, cholinergic neurons
located in the laterodorsal tegmentum and pedunculopontine tegmentum are also
important for orexin-cholinergic interactions. Indeed, orexins infused into the laterodorsal
tegmentum, much like the basal forebrain, induce arousal and increase wakefulness
(Thakkar et al. 2001; Xi et al. 2001; Espaa et al. 2001), which ultimately suggests that
cholinergic innervation to the basal forebrain is vital for maintaining arousal (Ohno and
Sakurai 2008; Yamanaka et al. 2003; Zhou et al. 2015). Both empirical and heuristic
observations indicate that attentional function is dependent upon a state of arousal. This
phenomenon is observed in narcoleptic patients where arousal and, often, attentional
performance is impaired significantly. Together, this suggests that orexins are not only
important, but necessary for proper attentional function. Functionally, orexins can
modulate attention through several putative mechanisms. As previously mentioned,
orexin neurons send robust projections to the basal forebrain, but also directly to the
neocortex. Administration of OxA directly into the basal forebrain not only increases
cortical acetylcholine release, but also enhances attentional capacity (Fadel et al. 2005;
Zajo et al. 2016). Moreover, direct OxA administration into the basal forebrain also
increases local glutamate release, in turn modulating the activity of basal forebrain
cholinergic neurons (Frederick-Duus et al. 2007). Basal forebrain cholinergic neurons
also receive help from GABAergic neurons facilitating arousal as orexins have been
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found to directly excite wake promoting non-cholinergic neurons of the basal forebrain
(Arrigoni et al. 2010). Lastly, direct infusion of orexin-B into the prefrontal cortex
enhances accuracy during a highly demanding attentional task. Mechanistically, it was
determined that the attentional enhancement occurred through excitation of the thalamocortical synapses activated by basal forebrain cholinergic neurons (Lambe et al. 2005).
1.5.6: Orexin function degenerates during aging
Because orexins play such a vital role in maintaining physiological homeostasis,
dysregulation of the orexin system can result in a multitude of cognitive and behavioral
deficits. This phenomenon is most clearly exemplified in narcolepsy, which is hallmarked
by a selective loss of orexin neurons (Siegel 1999; Thannickal et al. 2009). While
narcoleptic symptomatology is classically defined by disruption in the sleep/wake cycle,
heuristic observations of narcoleptic patients have shown that narcoleptics display
additional cognitive dysfunction, including deficits in sustained attention and olfactory
discrimination (Rieger et al. 2003; Bayard et al. 2010; Naumann et al. 2006).
Interestingly these deficits in attention and olfactory discrimination also arise during
aging and early AD (Sarter and Turchi 2002; Wesson et al. 2010; Perry and Hodges
1999a; Hüttenbrink et al. 2013). The observed cognitive deficits in narcoleptics that arise
from the loss of orexin neurons may also correlate to age-related cognitive dysfunction.
Prior work from our lab and others has shown a selective age-related loss of orexin
neurons and/or their peptides and receptors (Kessler et al. 2011; Downs et al. 2007;
Porkka-Heiskanen et al. 2004; Sawai et al. 2010; Terao et al. 2002; Zhang et al. 2002).
Moreover, recent post-mortem analysis of brains from patients with AD suggests a
selective loss of orexin neurons (Davies et al. 2015; Fronczek et al. 2012). Collectively,
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these findings provide convincing evidence that orexins modulate the underlying neural
substrates of cognition and suggest that orexin-based therapeutics may be useful in the
treatment of age-related cognitive disorders.
1.5.7: Orexins and Alzheimer’s disease
Current research indicates that late-onset AD is an enormously complicated
disorder composed of abnormal interactions among a multitude of biological systems.
Although age is the strongest risk factor for AD (Hebert et al. 1995), the underlying
cause, or more likely, causes, are still being investigated. The main pathological
hallmarks of AD classically include amyloid-β plaques and neurofibrillary tangles. More
recently, AD pathology has been consistently associated with neuroinflammation, altered
insulin resistance, oxidative stress, and cerebrovascular dysfunction (Cavedo et al. 2018).
These pathologies have been classically intertwined with the cholinergic lesion observed
in AD (Mesulam 2013; Geula et al. 1998; Bergmann et al. 1978). More recently,
however, these pathologies may be interconnected to the orexin system. In a recent study,
the number of orexin neurons in AD patients was found to be reduced by 40% along with
a 14% reduction in OxA within patient cerebrospinal fluid (Fronczek et al. 2012).
However, more recent studies have found conflicting evidence, indicating that orexin
levels are elevated in the cerebrospinal fluid (CSF) of AD patients (Liguori et al. 2016;
Liguori 2017) and that increased OxA in the CSF correlates with amyloid-β42 levels
(Gabelle et al. 2017). Furthermore, orexins have been recently found to inhibit uptake
and degradation of amyloid-β in microglia (An et al. 2017). Despite these recent negative
associations with AD, orexins have also been shown to have neuroprotective and
cognitive enhancing effects. For example, in the SAMP8 mouse model of AD, ICV
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microinjection of OxA improves memory (Jaeger et al. 2002). Furthermore, orexin
receptor blockade in the CA1 region of the hippocampus impairs spatial memory retrieval
(Akbari et al. 2008; Akbari et al. 2006), while administration of OxA into the
hippocampus recovers impairments in learning and memory due to a painful stimulus
(Raoof et al. 2014). Lastly, recent work characterizing orexin receptors has demonstrated
that cells forming heterodimers between orexin receptors and the orphan receptor,
GPR103, exert a neuroprotective effect against AD via upregulation ERK1/2
phosphorylation (Davies et al. 2015; Chen et al. 2019).
1.5.8: Intranasal administration of orexins
The orexin system exerts a powerful influence over physiological and behavioral
states by interacting with systems involved in sleep/wakefulness, energy homeostasis,
addiction, stress responses, and cognition. These observations have given way to a
substantial interest in developing therapeutic agents that target orexin receptors (Chieffi
et al. 2017). To date, there are numerous selective and non-selective orexin receptor
antagonists that have been developed (Skudlarek et al. 2017; Smart et al. 2001; Steiner et
al. 2013; Roecker et al. 2016; Gotter et al. 2012a). Conversely, selective orexin receptor
agonists with preclinical or clinical efficacy are scarce (Mieda and Sakurai 2013;
Nagahara et al. 2015; Turku et al. 2017), ultimately leading to the use of orexin peptides
as the agonists of choice. While early work in canine narcolepsy models suggested that
systemic delivery of orexins could have therapeutic efficacy (Fujiki et al. 2003; John et
al. 2000), concerns surrounding this route of administration include peripheral
degradation, poor delivery across the blood-brain-barrier, and significant peripheral side
effects (Dhuria et al. 2009; Hallschmid and Born 2008; Kastin and Akerstrom 1999). To
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circumvent these issues, intranasal administration has been proposed as a feasible
treatment route to target orexins and various other neuropeptides to the CNS (Dhuria et
al. 2010; Hanson and Frey 2008; Lochhead and Thorne 2012). Intranasal administration
of neuropeptides provides several benefits over systemic administration including
targeted delivery to the CNS, reduced peripheral complications, and complete bypass of
the blood-brain-barrier (Hanson and Frey 2008; Meredith et al. 2015; Lochhead and
Thorne 2012; Spetter and Hallschmid 2015). The extent and time course of peptide
delivery to the CNS depends on several factors such as peptide size, lipophilicity, and
transportation methods from the olfactory mucosa into the brain (Lochhead and Thorne
2012; Dhuria et al. 2010; Meredith et al. 2015; Spetter and Hallschmid 2015). The
mechanisms of intranasal orexin delivery to the CNS are not completely understood but
available data suggest that proteins transported to the CNS start at olfactory and
trigeminal nerve constituents of the nasal epithelium and proceed to the olfactory bulb
and sensory/spinal trigeminal regions of the pons, the CNS origins of chemosensory and
somatosensory innervation, respectively, of the nasal mucosa. Once in the CNS, peptides
can then diffuse to various rostral and caudal brain regions (Thorne et al. 2004; Lochhead
and Thorne 2012; Thorne et al. 2008). Brain penetration and distribution of peptides and
proteins may be affected by multiple factors including molecular weight, tertiary
structure, lipophilicity, and receptor localization. However, there are no broadlyapplicable predictive models, emphasizing the importance of peptide-specific
descriptions of distribution patterns in understanding behavioral and physiological effects
of intranasal administration.
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1.6: Summary
While cognitive deficits progress significantly from normal aging to mild
cognitive impairment and finally to AD, an early feature of these age-related cognitive
changes is a deterioration of attentional function (Sarter and Turchi 2002; Oken et al. 2012;
Rizzo et al. 2000; Perry and Hodges 1999b; Scinto et al. 1994). The attentional deficits that
occur during aging almost certainly involve the dysfunction of several neurotransmitter
networks; however, these deficits prominently include dysfunction of the basal forebrain
cholinergic system (BFCS) (Muir et al. 1992; Sarter and Bruno 1997; Robbins et al. 1997;
Whitehouse 2004; Hasselmo and McGaughy 2004). These early discoveries made the BFCS
a prominent target for treating age-related cognitive disorders (Robbins et al. 1997; Winkler
et al. 1998). Nevertheless, the cholinesterase inhibitors used to treat these disorders provide
only modest benefits on cognition and eventually lose their efficacy (Robbins et al. 1997;
Winkler et al. 1998; Francis et al. 1999; Siegfried 1993; Ringman and Cummings 2006).
Thus, age-related cognitive dysfunction is likely the consequence of a progressive
degeneration of various interacting neurotransmitter systems. Taken together, the age-related
cognitive deficits originally tied to BFCS dysfunction may ultimately arise from disruptions
to the afferent regulation of the BFCS. Indeed, research over the previous two decades has
keyed the hypothalamic orexin/hypocretin system as a prime contributor to the cognitive
decline observed during aging.
Orexin projections to the basal forebrain have been shown to modulate cognition
through connections to various telencephalic brain regions including the PFC, the agranular
insular cortex—the putative ‘interoceptive cortex’—, and the BFCS (Fadel and Burk 2010;
Arrigoni et al. 2010; Huang et al. 2006; Lambe et al. 2005). Additionally, administration of
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OxA has been shown to facilitate attentional processing through activation of basal forebrain
cholinergic neurons, which in turn alter cortical acetylcholine release (Fadel et al. 2005;
Fadel and Burk 2010; Zajo et al. 2016). OxA administration also modulates glutamatergic
thalamocortical synapses and facilitates attention (Lambe et al. 2005; Huang et al. 2006;
Song et al. 2006). Because orexins play such a vital role in maintaining physiological
homeostasis, dysregulation of the orexin system can result in a multitude of cognitive and
behavioral deficits. This phenomenon is most clearly exemplified in narcolepsy, which is
hallmarked by a selective loss of orexin neurons (Siegel 1999; Thannickal et al. 2009).
While narcoleptic symptomatology is classically defined by disruption in the sleep/wake
cycle, heuristic observations of narcoleptic patients have shown that narcoleptics display
additional cognitive dysfunction including deficits in sustained attention and olfactory
discrimination (Rieger et al. 2003; Bayard et al. 2010; Naumann et al. 2006).
Interestingly, narcoleptic patients also show subtle similarities in the cognitive deficits,
namely deficits in attention and olfactory discrimination, that arise during aging and early
AD (Sarter and Turchi 2002; Wesson et al. 2010; Perry and Hodges 1999a; Hüttenbrink
et al. 2013). The observed cognitive deficits in narcoleptics that arise from the loss of
orexin neurons may also correlate to age-related cognitive dysfunction. Prior work from
our lab and others has shown a selective age-related loss of orexin neurons and/or their
peptides and receptors (Kessler et al. 2011; Downs et al. 2007; Porkka-Heiskanen et al.
2004; Sawai et al. 2010; Terao et al. 2002; Zhang et al. 2002). Moreover, recent postmortem analysis of brains from patients with AD suggests a selective loss of orexin
neurons (Davies et al. 2015; Fronczek et al. 2012). Collectively, these findings provide
convincing evidence that orexins modulate the underlying neural substrates of cognition
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and suggest that orexin-based therapeutics may be useful in the treatment of age-related
cognitive disorders.
Even though these observations provide a powerful framework for the therapeutic
potential of intranasal OxA, studies investigating the mechanisms responsible for these
behavioral observations remain limited. The available literature on intranasal orexin
administration has primarily focused on the non-selective OxA neuropeptide; therefore,
the contributions of each receptor to the behavioral and neurochemical observations
cannot be determined. The scarcity of in-vivo studies using OxB administration stem
from a multitude of reasons. These concerns are substantiated through work that shows
limited diffusion of OxB across the blood-brain-barrier due to its low-lipophilic
properties and rapid metabolic degradation by inactivating peptidases (Kastin and
Akerstrom 1999). The affinity of OxB for the OX2 receptor is roughly 10-fold higher
than its affinity for the OX1 receptor (Sakurai et al. 1998), making it difficult to draw
receptor-specific mechanistic conclusions about physiological or behavioral responses to
OxB. The development of a modified OxB peptide, [Ala11, D-Leu15]-OxB, with a
reported 400-fold higher affinity for the OX2 receptor vs. the OX1 receptor, (Asahi et al.
2003) may offer a more selective tool for dissecting relative contributions of the orexin
receptors to orexin peptide effects on physiological function (see (Putula et al. 2011) for
potential caveats surrounding the relative selectivity and potency of this compound for
the different orexin receptors in vitro). Ultimately, these studies were designed to assess
the mechanisms and therapeutic potential underlying intranasal orexin administration,
particularly as it relates to aging and age-related cognitive disorders.
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1.7: Overarching hypothesis
I hypothesize that intranasal orexin administration improves age-related cognitive
deficits by altering neurotransmission within brain regions that modulate attentional
function (Figure 1.1). The pharmacological mechanisms through which intranasally
administered orexin peptides improve cognition have yet to be fully determined.
Accordingly, the studies planned here will expand upon the neurochemical and behavioral
correlates of cognition within cholinergic, glutamatergic and GABAergic systems after
intranasal orexin administration. Here, I will determine the mechanisms and therapeutic
potential of intranasal OxA and intranasal [Ala11, D-Leu15]-OxB using
immunohistochemistry, in-vivo microdialysis, and attentional set-shifting. I expect to find
the following after intranasal orexin administration:
•

Increased neuronal activation (i.e., c-Fos expression) within the PFC, BFCS,
the insular cortex, and the hippocampus in young and aged animals treated
with intranasal OxA

•

Intranasal OxA will increase ACh and glutamate efflux in the PFC of young
and aged animals

•

Intranasal [Ala11, D-Leu15]-OxB administration will increase neuronal
activation (i.e., c-Fos expression) of cholinergic neurons in the BFCS

•

Intranasal OxA will decrease the number of trials needed to complete the
extradimensional (EDS) stage of the attentional set-shifting task in young and
aged animals
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Figure 1.1 Summary figure for the overarching hypothesis. I
hypothesize that intranasal orexin administration improves age-related
cognitive deficits by altering neurotransmission within brain regions
that modulate attentional function. Specifically, I predict that intranasal
orexin administration will increase neuronal activation and
neurotransmitter release in brain regions that support proper cognitive
functioning during aging.
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CHAPTER 2
GENERAL MATERIALS AND METHODS
2.1: Rationale for animal care and use
Experimental methods, materials, and procedures for immunohistochemistry and
in-vivo microdialysis were generally as described in our published works examining
intranasal OxA administration in young and aged animals (Calva et al. 2018; Calva and
Fadel 2018). Animal care and use practices, including rationale for use and number of
animal subjects, were performed in accordance with protocols written under guidelines of
the National Institutes of Health Guide for the Care and Use of Laboratory Animals and
approved by the Institutional Animal Care and Use Committee (IACUC) at the
University of South Carolina (Animal Use Protocols #2248, #2409). Male Fischer
344/Brown Norway F1 hybrid rats (FBN/F1; Harlan/NIA) were utilized for all
experiments. Young and aged animals were approximately 3-4 months and 26-28
months, respectively, upon arrival to the animal facility. The FBN/F1 strain has been
extensively used by our laboratory and others for neurobiology of aging studies, because
they have reduced susceptibility to several non-neurological age-related complications
(e.g., intraperitoneal tumors) observed in other strains, even well into the third year of life
(Lipman et al. 1996; Turturro et al. 1999). Therefore, we utilized the FBN/F1 hybrid
strain in order to compare the effects of intranasal orexin administration on the
neurobiological systems that are dysregulated during aging. As further proof of concept,
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this strain of rat has been extensively used in our lab to study orexin-aging connections
(Hagar et al. 2017; Kessler et al. 2011; Stanley and Fadel 2011; Stanley et al. 2012). All
animals were housed in an environmentally controlled animal facility and kept on a 12:12
light: dark cycle with lights on at 07:00 hours. Animals were allowed access to standard
rat chow and water ad libitum and all experiments were performed during the light phase
of the light: dark cycle. Several measures were taken to minimize animal suffering during
experimentation, including careful monitoring of anesthetic depth during surgery,
administration of analgesics to ease post-operative pain, and using a within-subjects
multi-session design for in-vivo microdialysis, thus reducing the number of animals
needed to achieve equivalent statistical power. In lieu of performing power analyses to
determine group sizes, prior studies using comparable treatment group sizes were
consulted in order to obtain appropriate sample sizes for each experiment. The
experimenter performing intranasal administration was not blinded to treatment
conditions (saline vs. OxA/ [Ala11, D-Leu15]-orexin-B) during experimentation; however,
the experimenter was unaware of these treatment conditions while conducting cell counts
during histological imaging.
2.2: Timeline for immunohistochemistry and in-vivo microdialysis experiments
Upon arrival, each batch of animals used for the immunohistochemistry or in-vivo
microdialysis experiments followed the timeline outlined in Figure 2.1. Day 0 represents
the day of arrival for each batch of animals used at the University of South Carolina
School of Medicine animal facility. Beginning on Day 1, animals were handled and
habituated for 7 days total (Day 0-7). After 1 week, animals were assigned to either the
immunohistochemistry (c-Fos) or in-vivo microdialysis experimental groups. For the c-
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Figure 2.1 Experimental timeline for immunohistochemistry and in-vivo
microdialysis
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Fos experiments, animals received a daily habituation to intranasal saline for 7 days (Day
8-14). On testing day (Day 15), each rat received intranasal saline (50 µL of 0.9% saline),
intranasal OxA (50 µL of a 100 µM solution; Enzo Life Sciences; Farmingdale, NY,
USA), or intranasal [Ala11, D-Leu15]-orexin-B (50 µL of a 100 µM solution; Tocris
Bioscience; Minneapolis, MN, USA) and was euthanized 2 hours post-administration.
Processing of brain tissue, immunohistochemistry, cell counts, and data analysis started
on Day 16 and continued until complete for each batch of rats used for c-Fos analysis.
For the in-vivo microdialysis experiments, guide cannula surgery was performed during
Days 8-10. Animals were allowed at least two full days of recovery before habituation in
the microdialysis bowls. Following recovery, animals received a week of daily
habituation to intranasal saline (Day 12-18). The first microdialysis session was
performed on Day 19 and the second session on Day 21. Microdialysis experiments were
counterbalanced so that half of the animals received OxA in the first session and saline in
the second session; the order was reversed for the other half of the animals. On the day
following the second microdialysis session (Day 22), animals were euthanized, their
brains processed for histochemical verification of probe placement, and highperformance liquid chromatography (HPLC) analysis of dialysate samples began.
2.3: Stereotaxic surgery for implantation of guide cannulae
The stereotaxic surgical device allows for researchers to implant probes, fibers,
and other devices or to inject substances into brain regions with extreme precision.
Animals are first anesthetized, and their heads shaved to allow for access to the skin just
above the skull. Once mounted in the stereotaxic device, the animal is sterilized and
given an incision upon the midline of their head to access the skull surface. Once cleaned,
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the bone sutures on the animal’s skull are used to locate lambda and bregma in order to
determine proper placement for the microdialysis probe. While under ketamine (90
mg/kg)/xylazine (2-10 mg/kg) anesthesia, animals used for in-vivo microdialysis received
a single guide cannula (BASi, West Lafayette, IN, USA) inserted into the prefrontal
cortex (PFC) at AP +2.8 mm, L ±0.5 mm, and DV -2.8 mm relative to bregma (Figure
2.2). Coordinates for guide cannula implantation were obtained from the Paxinos and
Watson rat brain atlas (Paxinos and Watson 1998). The intracerebral guide cannula was
anchored in place using two to three skull screws and dental cement. Guide cannula
placement was counterbalanced so that left and right hemispheres were represented
equally. During the procedure, all animals were given a single dose of buprenorphine
(0.01 mg/kg, s.c) to ease post-operative pain and were monitored until complete recovery.
2.4: Immunohistochemistry and immunofluorescence
Upon arrival, both young and aged animals were assigned to receive intranasal
administration of either vehicle (50L of 0.9% saline) or OxA (50L of a 100M
solution; Enzo Life Sciences, Farmingdale, NY, USA). Animals used for
immunohistochemistry were received in separate batches. For each batch, both treatment
conditions were equally represented; however, treatment order within each batch was
pseudo-randomly determined before each test day. Each animal received several days of
gentle handling and habituation to intranasal saline administration prior to the test day.
Briefly, each animal was loosely blanketed with a small cloth and held in a supine
position so that only the animal’s snout was protruding from a small opening. No
restraint or anesthesia was used during intranasal habituation or treatment. On the test
day, each rat was administered 50μL of saline or OxA. Intranasal administration of the
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Figure 2.2 Probe placement verification with an acetylcholinesterase
background stain. Intracerebral guide cannula was placed into each animals’
prefrontal cortex at the coordinates: AP +2.8 mm, L ±0.5 mm, and DV -2.8 mm
relative to bregma. An acetylcholinesterase background stain yielding a redbrown hue is indicative of the location of the microdialysis probe.
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entire 50μL volume was delivered in four 12.5 L aliquots (a total of 25 µL in each naris)
over a 2-3-minute period. A separate set of young animals were assigned to receive either
vehicle or a modified orexin-B peptide (50L of a 100M solution) serving as a potent
and selective OX2 receptor agonist ([Ala11, D-Leu15]-orexin-B; Tocris Bioscience;
Minneapolis, MN, USA). While rat-to-human conversion of doses holds many caveats,
based on conversion factors suggested by Nair and Jacob (Nair and Jacob 2016), our 5
nmol dose in rats would approximately equate to a 200 nmol dose in humans. While no
studies to date have described intranasal [Ala11, D-Leu15]-OxB administration in humans,
previous work in human narcoleptic patients suggests that a 435 nmol dose of intranasal
OxA enhances wakefulness and attention. Given the lack of available comparative
evidence, our doses of orexin appear practical.
Treatment group assignment for all immunohistochemistry experiments was
pseudorandomized for each batch of animals such that treatment order (i.e. intranasal
saline or intranasal orexin) was counterbalanced and equally represented for each batch.
All animals were handled and habituated to intranasal saline administration prior to the
treatment day. On treatment day, animals received their designated treatment and were
subsequently sacrificed under heavy isoflurane anesthesia and perfused with phosphate
buffered saline and 4% paraformaldehyde 2 hours post-administration to observe optimal
c-Fos expression (Kaczmarek 1992). After an overnight post-fixation, each brain was
coronally sectioned at a 50 µm thickness using a vibratome. A 1:4 serial sectioning
method was utilized, thus allotting 200 µm between each representative section. Sections
not immediately used for immunohistochemistry were stored in 30% sucrose/30%
ethylene glycol anti-freezing solution at -20C until use. Single and dual-label
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immunohistochemistry followed similar protocols, where free-floating sections were
incubated with a rabbit anti-c-Fos primary antibody (1:5000; Millipore, Billerica, MA,
USA; catalog No. ABE457; RRID AB_2631318) for 48 hours at 4°C, followed by a
biotinylated donkey anti-rabbit secondary antibody (1:1000; Jackson ImmunoResearch
Laboratories Inc.; West Grove, PA, USA; code No. 711-065-152; RRID AB_2340593)
for 1.5 hours at 23°C (RT), and a horseradish peroxidase conjugated streptavidin tertiary
antibody (1:1600; Jackson ImmunoResearch Laboratories Inc.; code No. 016-030-084;
RRID AB_2337238) for 1 hour at 23°C (RT). Staining for c-Fos was developed with
0.3% hydrogen peroxide and nickel-cobalt enhanced diaminobenzidine (DAB) to yield
blue-black immunopositive nuclei. Dual-label staining for either choline acetyltransferase
(ChAT) or parvalbumin (PV) used c-Fos stained sections that were subsequently
incubated in either a goat anti-ChAT (1:3000; Millipore, Temecula, CA, USA; catalog
No. AB144; RRID AB_90650) or a mouse anti-PV (1:4000; Sigma, St. Louis, MO, USA;
catalog No. P3088; RRID AB_477329) primary antibody for 48 hours at 4°C. Secondary
and tertiary steps followed with incubations in either an unlabeled donkey anti-goat
(1:200; Jackson ImmunoResearch Laboratories Inc.; code No. 705-005-003; RRID
AB_2340384) or an unlabeled donkey anti-mouse (1:200; Jackson ImmunoResearch
Laboratories Inc.; code No. 715-005-150; RRID AB_2340759) secondary antibody for 2
hours at 23°C (RT), followed by incubations in either a goat peroxidase anti-peroxidase
(1:500; Jackson ImmunoResearch Laboratories Inc.; code No. 123-005-024; RRID
AB_2338953) or a mouse peroxidase anti-peroxidase (1:500; Jackson ImmunoResearch
Laboratories Inc.; code No. 223-005-024; RRID AB_2339261) tertiary antibody for 1.5
hours at 23°C (RT). Immunostaining for ChAT or PV were developed with 3% hydrogen
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peroxide and DAB to yield brown immunopositive cell bodies. Using a 0.15% gelatin
solution, sections were mounted onto slides and allowed to dry overnight before
dehydration, delipidation, and cover-slipping with DEPEX mounting medium.
In order to perform a qualitative examination of where intranasal OxA distributed
within the brain, a subset of animals (n=4, young; n=4, aged) received intranasal
administration of either saline or a modified OxA peptide labeled with a greenfluorescent fluorophore (5(6)-FAM-(Glu1)-OxA trifluoroacetate salt; BACHEM;
Bubendorf, Switzerland). Animals receiving the fluorescein-tagged OxA peptide received
50 L of a 500 M dose split into four 12.5 µL increments over a two-minute period and
were sacrificed thirty minutes post-treatment. This timepoint was chosen based upon a
previous study showing peak appearance of 125I–OxA in the CNS thirty minutes after
intranasal delivery (Dhuria et al. 2009). Perfusion and brain sectioning were as described
above. Sections were mounted onto slides with 0.15% gelatin, dried overnight,
dehydrated only and cover-slipped using Permount mounting medium.
2.5: Microscopy and imaging
Histological experiments for single-labeled (c-Fos) cells, double-labeled (c-Fos +
ChAT or PARV) cells, and AChE background staining were visualized using a Nikon
E600 microscope fitted with a CoolSNAP digital camera (Roper Scientific, Trenton, NJ,
USA). Fluorescence images were visualized using a Nikon E600 microscope or a Leica
SP8 multiphoton confocal microscope (Leica Microsystems; Wetzlar, Germany)
equipped with LAS AF 3 analysis software (Leica Microsystems; Wetzlar, Germany).
Immunoperoxidase photomicrographs were captured using IP Lab Software (Scanalytics;
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Trenton, NJ, USA). Images were imported into Adobe Photoshop 6.0 (Adobe Systems;
San Jose, CA, USA) to adjust the image size and to make minor alterations to contrast
and brightness. Brain regions where photomicrographs were captured are highlighted in
the results via modified illustrations from the Paxinos and Watson rat brain atlas (Paxinos
and Watson 1998).
2.6: Comparative heatmap of c-Fos expression
A comparative heat map was generated utilizing single-label c-Fos data to better
visualize differences in region-specific neuronal activation between intranasal treatment
groups (i.e. saline, OxA, or [Ala11, D-Leu15]-OxB) across young and aged animals. The
treatment groups used for producing the heat map were as follows: 1) Young saline (YS),
2) Young-OxA (YOA), 3) Young [Ala11, D-Leu15]-OxB (YOB), 4) Aged saline (AS), and
5) Aged OxA (AOA). For each brain region mapped, the data were computed across the
total number of animals for each group with a minimum of n=7 animals per treatment
group. The scaled colorimetric data within the heat map is represented as the ratio of
average c-Fos densities for each brain region between the different treatment groups. All
treatment groups were normalized to saline groups to yield the resulting heat map
conditions: 1) YOA/YS, 2) YOB/YS, 3) AOA/AS, 4) AS/YS. The YOA and YOB
experiments were performed at different time points; therefore, these groups were
normalized using the corresponding YS group. In contrast, the AS/YS ratio was
calculated using the average c-Fos densities pooled across both YS groups. Data
calculations and analyses for the heat map were performed using Microsoft Excel 2016
for Macintosh (Microsoft Corporation, Redmond, WA, USA). The data was then
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imported into MATLAB R2018a (MathWorks Inc., Natick, MA, USA) for generation of
the colorimetric heat map.
2.7: In-vivo microdialysis
The in-vivo microdialysis technique is a commonly used tool in neuroscience
research because of its ability to assess extracellular efflux of neurotransmitters real-time
in freely behaving animals. The microdialysis probe itself is a semi-permeable membrane
which, when in the brain, can collect neurotransmitters and neuropeptides. In
concordance with the immunohistochemistry experiments, animals used for the in-vivo
microdialysis experiments arrived in separate batches. Beginning 3 days after cannula
implantation, animals were habituated in microdialysis bowls for 3-4 days and habituated
with intranasal saline for 7 days. On microdialysis days, guide cannula stylets were
removed and substituted with a microdialysis probe (BASi, West Lafayette, IN, USA)
that extended 2 mm past the guide cannula. Probes were perfused at a 2 l/min flow rate
with artificial cerebrospinal fluid (aCSF, pH 7.4) containing: 150 mM NaCl, 3mM KCl,
1.7mM CaCl2, 0.9 mM MgCl2, and 4.9 mM D-glucose. Neostigmine bromide (50 nM;
Sigma) was added to the aCSF to increase recovery of acetylcholine in collected
dialysates. Dialysate collection started after a 3-hour discard period. Microdialysis
sessions consisted of one hour (4 x 15-minute collections) of baseline collections
followed by intranasal vehicle (0.9% saline) or OxA (100 µM; Enzo Life Sciences),
administered in a total volume of 50 µl in 12.5 l increments over a 2-minute period.
The individual performing intranasal administration was not blinded to treatment
conditions. Dialysate collection then continued for two hours (8 x 15-minute collections)
post-treatment. Upon collection, dialysates were stored at -80ºC until analysis using
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HPLC. All animals underwent two separate microdialysis sessions with an off day inbetween and experiments were counterbalanced so that half of the animals received
vehicle during session one, while the other half received OxA in session one. The day
following the last microdialysis session, rats were euthanized and their brains processed
for future probe placement verification using an acetylcholinesterase (AChE) background
stain. Probe placement verification was performed after all HPLC samples were run for
each respective animal. Any probe placement visualized outside the medial PFC excluded
the animal from the study.
2.8: High-performance liquid chromatography and chromatogram analysis
Each 30 µl dialysate was split prior to analysis by high performance liquid
chromatography with electrochemical detection (HPLC-ECD), with 20 µl analyzed for
ACh and 10 µl analyzed for glutamate. ACh was analyzed using an HTEC-510 HPLCECD (EicomUSA; San Diego, CA, USA). Briefly, 20 l of each dialysate was loaded
into the AC-GEL separation column (2.0 ID x 150mm; EicomUSA) maintained at a
constant 33ºC in combination with mobile phase (pH 8.5) containing 49.4 mM potassium
bicarbonate (KHCO3), 134.3 M ethylenediaminetetraacetic acid disodium (EDTA-2Na),
and 1.23 mM sodium 1- decanesulfonate. After analyte separation, post-column
derivatization of ACh was attained through use of an AC-ENYM II enzyme reactor (1.0
ID x 4 mm; EicomUSA) containing acetylcholinesterase and choline oxidase, which
generates hydrogen peroxide (H2O2) proportional to the amount of ACh present. The
H2O2 is further broken down and detected on a platinum working electrode with an
applied potential of +450 mV. The amount of ACh in each sample was measured by
comparison with a three-point external standard curve with values predicted to be in
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range of the collected dialysates. The limit of detection for this analysis was
approximately 5 fmol/injection.
Glutamate levels in brain dialysates were analyzed using a CC-32 HPLC-ECD
(BASi; West Lafayette, IN, USA) with modifications. First, 10 l of each dialysate was
loaded into the GU-GEL separation column (4.6 ID x 150mm; EicomUSA) in
conjunction with a mobile phase (pH 7.2) containing 60 mM ammonium chlorideammonium hydroxide, 134.3 nM EDTA-2Na, and 686 M
hexadecyltrimethylammonium bromide. After separation, post-column derivatization of
glutamate was attained using an E-ENZ enzyme reactor (3.0 ID x 40 mm; EicomUSA)
containing glutamate oxidase, which generates H2O2 proportional to the amount of
glutamate present. The H2O2 is further broken down and detected on a 3.0 mm glassy
carbon electrode (BASi) coated with a horseradish peroxidase osmium polyvinylpyridine
solution (0 mV applied potential). The amount of glutamate in each dialysate was
measured by comparison with a three-point standard curve using external standards
expected to be in range of the collected dialysates. The limit of detection for this method
was approximately 3 fmol/injection.
2.9: Attentional set-shifting paradigm
Cognitive impairment, particularly attentional dysfunction, is a principal feature
of several neuropsychiatric and neurological disorders including narcolepsy (Rieger et al.
2003) and AD (Sarter and Turchi 2002; Perry and Hodges 1999b). These observed
behavioral deficits stem, at least in part, from dysfunction within the prefrontal cortex
(PFC) (Dannhauser et al. 2005; Hao et al. 2005; Sampath et al. 2017). Indeed, although
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the ability to achieve simple cognitive tasks often remains intact, patients with
neurological disorders often present with deficits in the ability to modify responses to
complex behavioral tasks. In order to establish the homologous brain structure to the PFC
in rodents, Birrell and Brown developed an attentional set-shifting task modeled after the
Wisconsin Card Sorting Test (WCST) (Birrell and Brown 2000). In humans, the WCST
is used to evaluate strategy-switching deficits in patients that have frontal lobe
dysfunction (Lie et al. 2006; Nyhus and Barceló 2009). In primates, the medial prefrontal
cortex facilitates the capacity to shift attention to different features of complex stimuli
(Owen et al. 1991; Dias et al. 1996; Dias et al. 1997).
In rodents, the attentional set-shifting task takes each animal through a series of
increasingly difficult tasks in which they must dig in small containers to locate a food
reward (Birrell and Brown 2000). The specific procedures for our attentional set-shifting
task were adapted and modified from previous studies using similar methods (Birrell and
Brown 2000; Lapiz-Bluhm et al. 2008; Snyder et al. 2012; Barense 2002; Liston et al.
2006; Bissonette et al. 2013). Young and aged FBN/F1 rats were approximately 3-4
months and 26-28 months, respectively, upon arrival to the animal facility. Upon arrival,
both young and aged animals were assigned to receive intranasal administration of either
vehicle (50L of 0.9% saline) or OxA (50L of a 100M solution; Enzo Life Sciences,
Farmingdale, NY, USA). All animals were acclimatized to individual housing for at least
4 days prior to the start of any behavioral procedures. For approximately one week prior
to testing, each rat was maintained on a food restricted diet of approximately 14g per day,
such that by testing day, each rat weighed approximately 80-90% of their free-feeding
body weight. Each animal received several days of gentle handling and habituation to
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intranasal saline administration prior to the testing day. All behavioral experiments were
conducted during the light portion of the cycle, between 07:00 and 19:00 h. Our testing
apparatus was a custom-built black rectangular Plexiglas arena with inner dimensions of
75L x 40W x 30H (Snyder et al. 2012). The testing arena contained a black Plexiglas
removable divider to separate one-third of the arena from the remaining two-thirds of the
arena. This smaller portion of the arena served as the starting box for each rat and as a
holding area between each trial. Each trial began after lifting the removable divider,
allowing the rats to access the remainder of the arena. The larger portion of the divided
arena contained an irremovable and opaque Plexiglas panel to split the arena into two
sections. These two sections served as the holding area for the digging bowls. A visual
representation of the testing arena is shown in Figure 2.3. The digging pots used for these
experiments were small plastic containers (internal rim diameter 7 cm; depth 3.5 cm).
Each digging pot was distinguished by a pair of cues along two different stimulus
dimensions: (1) the digging medium held in each pot and (2) an odor applied to the rim of
each pot. The relevant/irrelevant dimensions and the positive/negative cue pairs for each
stage of the task are shown in Table 2.1. To mark each digging pot with an odor,
approximately 50 µl of extract was initially applied to the inner rim of the pot. Each
digging pot receives only one odor and a different pot is used for each combination. No
specific odors or media are necessary for this experiment; however, odor and media
pairings should be different enough for each animal to discriminate between (i.e. do not
pair lemon & lime or wood beads & plastic beads). The reward used for these
experiments, buried approximately 2 cm beneath the surface of each medium, was a
‘bacon softie’ broken into small pieces. For each trial, a small amount of reward was
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Figure 2.3 Representation of the testing
arena used for the attentional set-shifting
experiments. The dotted line represents the
removable divider while the navy-blue
circles represent the digging pots.
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Table 2.1 Attentional set-shifting task stages progressing from simple discrimination
to the extradimensional shift.
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ground and applied to the surface of both pots to ensure that each animal was digging
correctly based upon the positive cues rather than by smelling the food reward. After the
animals were food restricted for at least 5 days, the 3-day behavioral procedure was
conducted in the following manner:
Habituation Day (Day 1): before receiving their daily ration of standard rat chow,
rats were trained to dig reliably in each pot for a food reward (bacon softie). First, two
unscented plastic digging pots are placed into the home cage and baited. Each animal is
first allowed to retrieve the reward from both pots without being covered. If the animal
has not retrieved both food rewards after 5 minutes, the animal is given a ‘time-out’
period of 30 minutes and subsequently retried. Ultimately, each animal is required to dig
for the food reward in each pot in 3 trials of 5 minutes each, with the food reward
covered with an increasing amount of sawdust during each exposure. After the animal is
digging reliably, it is placed in the testing arena and habituated to digging in the same
manner described above.
Training Day (Day 2): before receiving their daily ration of standard rat chow,
rats are trained on a simple discrimination (SD) task to a criterion of six consecutive
correct trials. Each trial during the discrimination tasks was timed for up to 10 minutes. If
the animal did not retrieve the reward after 10 minutes, a non-digging response, or
‘error’, was recorded. Any animal with six consecutive errors was subsequently excluded
from further experimentation. All rats start by learning to associate the food reward with
the positive odor cue (the starting media is sawdust in both digging pots). In these
experiments, rosemary and orange were used as the odors. After six consecutive correct
trials, the animals were then trained to discriminate between two different media to
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achieve a reward. For these experiments, wood chips and gauze were used as the media.
All animals were trained with these odors and media with the positive and negative cues
randomly chosen for each animal. Importantly, the training stimuli were never used on
testing days to ensure that animals were not remembering odor or media pairings.
Testing Day (Day 3): before receiving their daily ration of standard rat chow, each
animal was tested on a series of five increasingly difficult discrimination tasks (Table
2.1). Again, the criterion used to proceed to the next stage of the experiment was six
consecutive correct digging responses. The first stage, like training day, was a simple
discrimination (SD) task. For the SD stage, half of the animals were required to
discriminate between two odors (i.e. strawberry vs. cinnamon) to retrieve a reward while
the other half were required to discriminate between two media (i.e. paper vs. felt) to
retrieve a reward. Only one of the digging pots (i.e. the positive cue pot) contained the
food reward. The second stage was a compound discrimination task (CD), where the
irrelevant stimuli from the other dimension were introduced, but the animal was still
required to discriminate between the two original stimuli from the SD stage. The third
stage was an intradimensional shift (IDS), where all new stimuli were used, however, the
task-relevant dimension was unchanged. For example, if the starting relevant dimension
was odor, the IDS stage would introduce new odors and media, however, the relevant
discriminatory dimension would still be odor. At this point in the task, the animal was
given its predetermined treatment (i.e. intranasal saline or intranasal OxA). This
timepoint for treatment was based upon the in-vivo microdialysis studies where the effect
of intranasal OxA on PFC acetylcholine efflux lasted approximately 30-60 minutes.
Because the ASST experiment lasts 2-3 hours for each animal, intranasal OxA was given
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just before the reversal learning stage (REV) of the task to allow for optimal assessment
of each treatment on prefrontal cortical function. The fourth stage of the task was a
reversal learning (REV) stage, where the relevant dimension remains the same, however,
the previously negative cue is now the positive cue. The fifth and final stage was an
extradimensional attentional shift (EDS). In this stage, all new stimuli are introduced, but
now the relevant dimension is changed. For example, if the starting relevant dimension
was odor, the EDS stage would introduce new odors and media, and the relevant
discriminatory dimension would change to media. For each animal, assignment to a
positive or negative cue, relevant starting dimension, and left-right positioning of the pots
within the arena were determined randomly in advance.
The main dependent measure in the attentional set-shifting task is the number of
trials required to reach the established criterion (6 consecutive correct responses). A
higher number of trials to completion indicates that the animal took more trials to
effectively learn a new rule. Due to the increasing difficulty of each stage, the latter
stages of the ASST experiment are expected to require more trials. The validity of the
attentional set-shifting task (ASST) as a model of prefrontal cortical dysfunction has been
demonstrated through lesioning studies to subsections of the rat prefrontal cortex.
Lesioning the rat medial prefrontal cortex (mPFC) results in selective deficits on the
extradimensional shift (EDS) stage of the ASST task, while lesions to the orbitofrontal
cortex (OFC) selectively disrupted performance on the reversal learning (REV) stage of
the task (Birrell and Brown 2000; McAlonan and Brown 2003). Furthermore, the validity
of this task in measuring deficits in age-related cognitive performance is demonstrated in
a study showing aged rats are impaired on the EDS stage of the task (Barense 2002).
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While this task is at times complex, it is a powerful experimental tool that can be used to
test hypotheses related to the mechanisms involved in treating age-related cognitive
dysfunction.
2.10: Statistics and data analysis
For all immunohistochemistry experiments, single-labeled (c-Fos) and doublelabeled (c-Fos + ChAT/PV) positive cells were counted within the confines of a reticle
fixed into the eyepiece of the microscope. Counts for each brain region were determined
by the total number of immunopositive nuclei/cells from two representative sections at
different levels of the rostro-caudal gradient. Single-label c-Fos data were expressed as
the density of immunopositive nuclei counted within the reticle area (c-Fos nuclei/mm2).
Statistical analyses of these data were analyzed by two-tailed unpaired t-tests (GraphPad
Prism 8; GraphPad Software for Macintosh, La Jolla, CA, USA). Double-labeled neurons
were expressed as the percentage of the total number of ChAT/PV neurons positive for cFos within the reticle area (i.e. % Double Labeled Neurons). Dual-label
immunoperoxidase data were analyzed by two-tailed unpaired t-tests. Significant effects
of treatment condition (i.e., OxA or saline) across age were determined by one-way
ANOVA followed by Tukey’s multiple comparisons test. A significance cutoff level of
p<0.05 was used for all analyses.
For the in-vivo microdialysis data, baseline neurotransmitter efflux was obtained
during the first four sample collections (i.e. timepoints 1-4) and averaged to yield mean
basal efflux. For each sample analyzed, a raw value was obtained and expressed as
pmol/20L for ACh and mol/l0L for glutamate. The graphed in-vivo microdialysis
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data are expressed as a percentage of the average baseline to account for individual
variation in basal neurotransmitter efflux. Data were analyzed using two-way repeatedmeasure ANOVAs (GraphPad Prism 8; GraphPad Software; La Jolla, CA, USA) with
treatment as a within-subjects variable, age as a between-subjects variable, and time as a
repeated measure. Significant interactions and main effects of treatment (i.e., OxA or
saline) or age were probed with Tukey multiple comparisons tests. A significance cutoff
level of p<0.05 was used for all analyses.
For the attentional set-shifting experiments, trials to reach criterion (6 consecutive
correct trials) were recorded for each rat. Because intranasal saline or intranasal OxA was
given just before the REV stage of the ASST experiment, the first three stages and the
final two stages were assessed differently. For the first 3 stages of the task (i.e. SD, CD,
IDS; before treatment), the groups were collapsed to assess differences in task
performance between young and aged animals. These results were analyzed using twotailed unpaired t-tests. For the final 2 stages of the task (i.e. REV, EDS; after treatment),
each treatment group was analyzed on its own using ordinary one-way ANOVAs
followed by Holm-Sidak multiple comparisons to determine significant differences
between the treatment groups. Data were represented as total number of trials to reach
criterion (y-axis) for each stage (x-axis). A significance cutoff level of p<0.05 was used
for all analyses.
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CHAPTER 3
EFFECTS OF INTRANASAL OREXIN-A OR [ALA11, D-LEU15]OREXIN-B ON NEURONAL ACTIVATION
3.1: Introduction
Because of orexin’s role in important physiological and behavioral phenomena
such as stabilization of sleep/wake states, food intake, addiction, and cognition there is
much interest in orexin receptors as potential therapeutic targets. The two orexin
peptides, OxA and orexin-B, act on two G protein-coupled receptors, with the orexin-1
receptor (Ox1R) binding OxA with high affinity and the orexin-2 receptor (Ox2R)
binding both OxA and orexin-B with relatively high affinity (Smart and Jerman 2002;
Ammoun et al. 2003; Gotter et al. 2012b; Leonard and Kukkonen 2014). Several singleand dual-orexin receptor antagonists have been developed (Smart et al. 2001; Gotter et al.
2012a; Steiner et al. 2013; Roecker et al. 2016; Skudlarek et al. 2017) but there is a
paucity of selective orexin agonists that might have experimental or clinical utility
(Mieda and Sakurai 2013; Turku et al. 2017). Administration of the native peptides,
meanwhile, is limited by potential peripheral side effects and limited ability to target the
brain due to peripheral degradation and the blood-brain barrier. One route that has been
suggested for brain delivery of orexins and other neuropeptides is intranasal
administration (Hallschmid and Born 2008; Hanson and Frey 2008; Dhuria et al. 2009;
Lammers 2011; Spetter and Hallschmid 2015). Intranasal OxA, for example, has been
shown to ameliorate attentional deficits produced by sleep deprivation in non-human
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primates (Deadwyler et al. 2007). Rodent studies have further shown that intranasal OxA
increases food intake and locomotor activity (Dhuria et al. 2016). Finally, limited human
trials have suggested that intranasal OxA can ameliorate wakefulness, olfactory, and
cognitive correlates of narcolepsy (Hallschmid and Born 2008; Baier et al. 2011;
Weinhold et al. 2014a). Despite these intriguing findings, however, our understanding of
the anatomical and neurochemical mechanisms that may underlie the effect of intranasal
orexin on cognition and behavior remains extremely limited. Accordingly, the goal of this
first experiment was to use immunohistochemistry to directly examine the effects of
intranasal OxA and intranasal [Ala11, D-Leu15]-orexin-B on c-Fos expression, a marker
for neuronal activation (Kaczmarek 1992), in multiple phenotypic neurons of young and
aged rats.
3.2: Methods
The methods described herein are an abbreviated version of those described in
‘Chapter 2: General Materials and Materials’. Young (3-4 months, 250-300g) and aged
(26-28 months, 450-550g) male Fisher 344/Brown Norway F1 hybrid rats (Harlan/NIA)
were used for all experiments. Upon arrival, animals were randomly assigned to receive
intranasal administration of either vehicle (50 l of 0.9% saline), OxA (50 l of a 100
M solution; Enzo Life Sciences), or [Ala11, D-Leu15]-orexin-B (50 l of a 100 M
solution; Tocris Bioscience). Separate batches of animals were used for the
immunohistochemistry experiments. On testing day, each batch of animals were dosed so
that each treatment on a given day was represented equally, with the order of treatments
for each animal being chosen pseudo-randomly. All solutions were administered in four
12.5 l increments over a two-minute period. Each animal was habituated with intranasal
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saline treatment for 7 days before experimentation. Beginning on day 8, animals received
their assigned treatment and were sacrificed two hours later, the time at which c-Fos
expression peaks (Kaczmarek 1992). Rats were anesthetized with isoflurane and perfused
with phosphate buffered saline (PBS) and 4% paraformaldehyde (PFA).
3.2.1: Immunohistochemistry
For single-label immunohistochemistry, free floating sections were incubated
with a rabbit-anti c-Fos antibody for 48 h at 4ºC followed by a biotinylated donkey antirabbit secondary antibody for 1.5 h at room temperature (RT), and horseradish peroxidase
conjugated streptavidin for 1 hour at RT. c-Fos staining was developed with 0.3%
hydrogen peroxide and nickel-cobalt enhanced diaminobenzidine to yield blue-black
immunopositive nuclei. For dual-label immunohistochemistry, the above steps were
followed with incubation in either a goat anti-choline acetyltransferase or mouse antiparvalbumin primary antibody for 48 h at 4ºC. Secondary and tertiary antibody
incubation followed using either unlabeled donkey anti-goat or unlabeled donkey antimouse for 2 hours at RT, and either goat peroxidase anti-peroxidase or mouse peroxidase
anti-peroxidase for 1.5 hour at RT. ChAT and PV immunoreactivity were developed with
3% hydrogen peroxide and diaminobenzidine to yield brown immunopositive cell bodies.
Sections were mounted onto slides with 0.15% gelatin, dried overnight, dehydrated,
delipidated, and cover-slipped using DEPEX mounting medium.
3.2.2: Immunofluorescence of peptide localization
In order to perform a qualitative examination of where intranasal OxA distributed
within the brain, a subset of animals (n=4, young; n=4, aged) received intranasal
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administration of either saline or a modified OxA peptide labeled with a greenfluorescent fluorophore 5(6)-FAM-(Glu1)-OxA trifluoroacetate salt. Animals receiving
the fluorescein tagged OxA peptide received 50 L of a 500 M dose split into four 12.5
µL increments over a two-minute period and were sacrificed thirty minutes posttreatment. This timepoint was chosen based upon a previous study showing peak
appearance of 125I–OxA in the CNS thirty minutes after intranasal delivery (Dhuria et al.
2009). Perfusion and brain sectioning were as described in the methods chapter above.
Sections were mounted onto slides with 0.15% gelatin, dried overnight, dehydrated only
and cover-slipped using Permount mounting medium.
3.2.3: Imaging
Histological experiments for single-labeled (c-Fos) cells, double-labeled (c-Fos +
ChAT or PV) cells, and AChE background staining were visualized using a Nikon E600
microscope fitted with a CoolSNAP digital camera. Fluorescence images were visualized
using a Nikon E600 microscope or a Leica SP8 multiphoton confocal microscope
equipped with LAS AF 3 analysis software. Immunoperoxidase photomicrographs were
captured using IP Lab Software. Images were imported into Adobe Photoshop 6.0 to
adjust the image size and to make minor alterations to contrast and brightness. To
indicate the approximate brain region where photomicrographs were obtained, diagrams
and schematics of brain regions in the results section were adapted from The Rat Brain
by Paxinos and Watson (Paxinos and Watson 1998).
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3.2.4: Statistics and data analysis
For all immunohistochemistry experiments, single-labeled (c-Fos) and doublelabeled (c-Fos + ChAT/PV) positive cells were counted within the confines of a reticle
fixed into the eyepiece of the microscope. Counts for each brain region were determined
by the total number of immunopositive nuclei/cells from two representative sections at
different levels of the rostro-caudal gradient. Single-label c-Fos data were expressed as
the density of immunopositive nuclei counted within the reticle area (c-Fos nuclei/mm2).
Statistical analyses of these data were analyzed by two-tailed unpaired t-tests (GraphPad
Prism 8; GraphPad Software for Macintosh, La Jolla, CA, USA). Double-labeled neurons
were expressed as the percentage of the total number of ChAT/PV neurons positive for cFos within the reticle area (i.e. % Double Labeled Neurons). Dual-label
immunoperoxidase data were analyzed by two-tailed unpaired t-tests. Significant effects
of treatment condition (i.e., OxA or saline) across age were determined by one-way
ANOVA followed by Tukey’s multiple comparisons test. A significance cutoff level of
p<0.05 was used for all analyses.
3.3: Results
3.3.1: Intranasal 5(6)-FAM-(Glu1)-orexin-A administration
To visually assess the possible modes by which intranasal OxA enters the brain
and to provide qualitative supporting evidence for the above results, we intranasally
administered a fluorescein-tagged OxA peptide 5(6)-FAM-(Glu¹)-OxA. This ultimately
revealed a distribution of the peptide to both rostral and caudal brain regions. Prior work
has suggested that intranasally delivered peptides reach the brain via diffusion along
sensory trigeminal pathways (Hanson and Frey 2008; Chapman et al. 2013; Spetter and
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Hallschmid 2015; Meredith et al. 2015). Therefore, we visualized delivery of the
fluorescein-tagged peptide in the principal sensory and spinal subdivisions of the
trigeminal nucleus (Figure 3.1; c, d), the sources of somatosensory innervation of the
olfactory mucosa. The fluorescein-tagged OxA peptide was also detected in cortical
regions, including the medial PFC (Figure 3.1; a, b). Due to the qualitative nature of these
experiments, a relatively modest treatment group sizes were used (n=4, young; n=4,
aged). This pattern of fluorescence was not observed following intranasal vehicle (saline)
administration (n=4, young; n=4, aged).

Figure 3.1 Localization of a green-fluorescent tagged OxA peptide in the brain after
intranasal administration. (a) Typical distribution of the fluorescent-tagged OxA
peptide (50 µl, 500 µM) in the PrLC after intranasal administration. Green
fluorescence indicates the appearance of the labeled peptide in the PrLC. (b)
Schematic indicating the approximate location (black-outlined square) within the
PrLC where fluorescence photomicrographs were obtained. (c) Typical distribution
of the fluorescent-tagged OxA peptide in the SpTrN. (d) Schematic indicating the
approximate location (black-outlined square) within the SpTrN where fluorescence
photomicrographs were obtained. Abbreviations: OxA, orexin-A; PrLC, prelimbic
prefrontal cortex; SpTrN, spinal trigeminal nucleus. Scale bar approximately 100 µm.
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3.3.2: Effects of intranasal orexin-A/ [Ala11, D-Leu15]-orexin-B on c-Fos expression
Intranasal administration of a fluorescein-tagged OxA peptide resulted in delivery
to both rostral (prefrontal cortex) and caudal (spinal trigeminal nucleus) brain regions in
young and aged animals indicating that intranasal orexins have the potential to quickly
and efficiently enter the brain. Accordingly, the goal of the next set of experiments was to
utilize immunohistochemistry to examine the effects of intranasal orexin delivery on cFos expression, a marker for neuronal activation.
3.3.2.a: Effects of intranasal orexin-A on c-Fos in young animals
Intranasal administration of OxA significantly increased c-Fos expression in
multiple brain regions of young animals (Table 3.1). In the cortex, intranasal OxA
increased c-Fos expression in the prelimbic (PrLC; t14=3.163, p=0.0069), agranular
insular (AIC; t14=3.291, p=0.0054), ventral orbital (VOC; t13=2.357, p=0.0348), and
piriform areas (PirC; t14=2.259, p=0.0404). Importantly, this effect was not a global
phenomenon as intranasal OxA failed to significantly alter c-Fos expression within the
claustrum, medial orbital cortex (MOC), and all regions of the hippocampus. In fact,
there was a strong trend for decreased c-Fos expression in the infralimbic cortex
(t14=2.092, p=0.0551) after intranasal OxA administration. We also considered the
possibility that intranasal OxA delivery may alter c-Fos expression within brainstem
regions involved in arousal. Indeed, intranasal OxA administration significantly increased
c-Fos expression within the pedunculopontine nucleus (PPTg; t13=2.692, p=0.0185)
(Table 3.1). As an example, density measurements for c-Fos were made using a 0.179
mm x 0.179 mm area in the center of the prelimbic cortex. For c-Fos counts within
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brainstem regions, measurements represent the total number of c-Fos positive nuclei
within the entire brain region.

Table 3.1 c-Fos densities (nuclei/mm2) in each brain region after intranasal vehicle
(saline) or intranasal OxA (50 μl, 100 µM) administration in young animals.

3.3.2.b: Effects of intranasal [Ala11, D-Leu15]-orexin-B on c-Fos in young animals
Intranasal [Ala11, D-Leu15]-OxB administration increased neuronal activation (cFos expression) in cortical and basal forebrain regions (Figure 3.2). In the cortex,
intranasal [Ala11, D-Leu15]-OxB administration significantly increased activation in the
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piriform cortex (t12 = 3.224, p = 0.0073) and the agranular insular cortex (t12 = 2.519, p =
0.0269) when compared to intranasal saline treated animals. In addition, there a was a
strong trend for increased activation in the prelimbic cortex (t12 = 2.033, p = 0.0647). In
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Figure 3.2 Neuronal activation (c-Fos expression density) in cortical
and basal forebrain regions following intranasal [Ala11, D-Leu15]OxB administration in young rats. Single-labeled c-Fos densities in
brain regions of animals treated with intranasal vehicle (saline; PirC,
AIC, PrLC, B/SI, n=7 rats) or intranasal [Ala11,D-Leu15]-OxB (50
μL, 100 µM; PirC, AIC, PrLC, B/SI, n=7 rats). Intranasal [Ala11, DLeu15]-OxB administration significantly increased c-Fos expression
within the PirC, AIC, and B/SI regions compared to vehicle treated
controls. There was a strong trend for increased c-Fos expression
within the PrLC after intranasal [Ala11, D-Leu15]-OxB
administration. Abbreviations: Ala, Alanine; D-Leu, D-Leucine;
OxB, orexin-B; PirC, piriform cortex; AIC, agranular insular cortex;
B/SI, nucleus basalis/substantia innominata; PrLC, prelimbic
prefrontal cortex. Error bars represent SEM. **p < 0.01, *p < 0.05
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the basal forebrain, intranasal [Ala11, D-Leu15]-OxB administration significantly
increased c-Fos expression within the nucleus basalis/substantia innominata (t12 = 3.663,
p = 0.0032) compared to intranasal saline treatment. Density measurements for c-Fos
were obtained using a 0.032 mm2 area within cortical regions and a 0.1225 mm2 area
within basal forebrain regions. While intranasal [Ala11, D-Leu15]-OxB did elicit increases
in c-Fos expression within some brain regions, intranasal OxA was able to increase c-Fos
expression across a broader range of the neuraxis, including the prefrontal cortex.
Therefore, the studies discussed henceforth focus on examining the effects of intranasal
OxA on neurotransmission and cognition.
3.3.2.c: Effects of intranasal orexin-A on c-Fos in aged animals
Intranasal administration of OxA significantly increased c-Fos expression in
multiple brain regions of aged animals (Table 3.2). In the cortex, intranasal OxA
increased c-Fos expression in the prelimbic cortex (PrLC; t14=4.276, p=0.0008) and
agranular insular cortex (AIC; t14=3.222, p=0.0061). Importantly, intranasal OxA did not
globally excite all brain regions as there were no significant changes in c-Fos expression
within the piriform cortex, ventral orbital cortex, nucleus accumbens shell, retrosplenial
cortex, and regions CA3 and CA1 of the hippocampus. Interestingly, there was a strong
trend for decreased c-Fos expression in the infralimbic cortex (t14=1.91, p=0.0769) after
intranasal OxA administration. We also considered the possibility that intranasal OxA
delivery may alter c-Fos expression in brain regions outside of the cortex. Indeed,
intranasal OxA also significantly increased c-Fos expression in the claustrum (Cl;
t14=3.055, p=0.0086) and in the dentate gyrus of the hippocampus (DG; t14=2.497,
p=0.0256) (Table 3.2). As an example, density measurements for c-Fos were made using
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a 0.179 mm x 0.179 mm area in the center of the prelimbic cortex. For brainstem c-Fos
counts, measurements represent the total number of c-Fos positive nuclei within the
entire brain region.
Table 3.2 c-Fos densities (nuclei/mm2) in each brain region after intranasal vehicle
(saline) or intranasal OxA (50 μl, 100 µM) administration in aged animals.

3.3.2.d: Effects of intranasal orexin administration across treatment and age
In addition to using intranasal [Ala11, D-Leu15]-OxB administration in young
animals, we have combined intranasal OxA administration and immunoperoxidase
staining for c-Fos in aged animals. To compare the effects aging and intranasal orexin
administration (i.e. OxA or [Ala11, D-Leu15]-OxB) in multiple brain regions, we
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constructed a heatmap using c-Fos expression ratios that were normalized to intranasal
saline treated controls (Figure 3.3). The range of ratios that we observed fell between 0.4
and 3.8, with lower scores lighter in color and higher scores darker in color. Scores above
1 indicate higher c-Fos expression when compared to saline treated controls and viceversa for scores below 1. On average, the effects of intranasal OxA treatment in aged
animals were more robust than the intranasal OxA treatment in young animals. Aged
animals also exhibited higher ‘basal’ c-Fos expression in most brain regions compared to
young animals, as indicated by the AS/YS treatment comparison. When comparing the
effects between the OxA and [Ala11, D-Leu15]-OxB treatments (i.e. YOA/YS vs.
YOB/YS), the YOA/YS group shows higher c-Fos expression ratios in most brain
regions. Accordingly, YOA/YS and YOB/YS groups qualitatively suggest that intranasal
OxA and intranasal [Ala11, D-Leu15]-OxB administration increases c-Fos expression in
young animals. Further statistical analysis on these differences from prior intranasal OxA
studies and from our data presented above (Figure 3.3) show that significant differences
in c-Fos expression are localized to specific brain regions. Specifically, in the cortex of
young animals, intranasal OxA significantly increased c-Fos expression in the piriform,
agranular insular, prelimbic, and ventral orbital cortices (Calva et al. 2018). Significant
increases in cortical c-Fos expression after intranasal [Ala11, D-Leu15]-OxB were limited
to the piriform and agranular insular cortices. In addition, the higher ratios present in the
AS/YS group suggests that aged animals exhibit higher basal levels of activation.
3.3.3: Effects of intranasal orexin-A on c-Fos expression in cholinergic neurons
Given the bounty of evidence showing that OxA activates the BFCS (Eggermann
et al. 2001; Fadel et al. 2005; Fadel and Frederick-Duus 2008; Arrigoni et al. 2010; Fadel
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Figure 3.3 Heatmap of c-Fos expression ratios after treatment with intranasal orexin. Treatment
groups: 1) YOA/YS (YOA and YS, n=8 rats), 2) YOB/YS (YOB and YS, n=7 rats), 3) AOA/AS
(AOA and AS, n=8 rats), and 4) AS/YS (AS, n=8 rats; YS, n=15 rats). Abbreviations: YOA/YS,
young-orexin-A/young saline; YOB/YS, young-[Ala11,D-Leu15]-orexin-B/young saline; AOA/AS,
aged-orexin-A/aged saline; AS/YS, aged saline/young saline; OxA, orexin-A; [Ala11,D-Leu15]-OxB,
[Ala11,D-Leu15]-orexin-B; PirC, piriform cortex; AIC, agranular insular cortex; PrLC, prelimbic
cortex; ILC, infralimbic cortex; VOC, ventral orbital cortex; Cl, claustrum; MS, medial septum;
VDBB, vertical limb of the diagonal band; HDBB, horizontal limb of the diagonal band; VP/SI,
ventral pallidum/substantia innominata; DG, dentate gyrus; CA3, cornu ammonis 3; CA1, cornu
ammonis 1; PPTg, pedunculopontine tegmentum; DR, dorsal raphe; LC, locus coeruleus.

and Burk 2010), we investigated if intranasal administration of OxA would elicit a
similar response in young and aged animals. Indeed, analysis by one-way ANOVA
indicated a significant effect of treatment for the medial septum (MS; F3,28 = 9.516,
p=0.0002), the vertical limb of the diagonal band (VDBB; F3,28=13.16, p<0.0001), the
horizontal limb of the diagonal band (HDBB; F3,28=12.56, p<0.0001), and the ventral
pallidum/substantia innominata (VP/SI; F3,28=12.34, p<0.0001). Further analysis with
Tukey’s multiple comparisons test revealed that intranasal OxA increased c-Fos
expression in cholinergic (ChAT+) neurons of the MS (p=0.0168), VDBB (p=0.0287),
and the VP/SI (p=0.0007) of aged animals compared to treatment with intranasal saline.
In young animals, Tukey’s multiple comparisons test revealed that intranasal OxA
increased c-Fos expression in ChAT+ neurons the VDBB (p=0.0002) and VP/SI
(p=0.0040). Interestingly, both portions of the diagonal band exhibited higher ‘basal’
levels of cholinergic neuron activation in aged animals compared to young animals
(Figure 3.4). Furthermore, intranasal OxA activated a higher percentage of ChAT+
neurons in the MS and HDBB in aged animals, although activation in the HDBB is quite
high under control conditions (Figure 3.4). Overall, data are expressed as the percentage
of ChAT+ neurons that also express c-Fos (Figure 3.4). Single and double labeled ChAT
neurons were counted within the same 0.45mm x 0.45 mm area for each basal forebrain
region so that direct comparisons could be established. As an example of the area where
c-Fos counts were obtained, the reticle area in the VDBB is depicted in the adapted
diagram (Figure 3.5). Double–labeled ChAT neurons of the VDBB are represented by
arrows pointing to the blue-black immunoreactivity for c-Fos and brown
immunoreactivity for ChAT (Figure 3.5)
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Figure 3.4 Activation of cholinergic neurons in the basal forebrain by intranasal
OxA administration. Intranasal OxA significantly increased the percentage of duallabeled ChAT neurons in the MS, VDBB, and VP/SI of aged animals (n=8, saline;
n=8, OxA). In young animals, intranasal OxA significantly increased c-Fos
expression in ChAT+ neurons within the VDBB and VP/SI. Data are represented as
the percentage of double-labeled (c-Fos/ChAT) neurons relative to the total number
of ChAT-positive neurons within the basal forebrain. #/$/*=p<.05, ^^=p<.01,
$$$/###/^^^=p<.001
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Figure 3.5 Representative photomicrograph depicting double-labeled cholinergic
(ChAT+) neurons in the basal forebrain. Intranasal OxA significantly increased
the percentage of dual-labeled ChAT neurons in the VDBB compared to vehicle
treated controls in both young and aged animals. The bold black square on the
schematic indicates the approximate location within the VDBB where cFos/ChAT counts and photomicrographs were obtained. The photomicrograph on
the right shows typical dual-label immunohistochemistry for c-Fos (blue/black)
and ChAT (brown) neurons within the VDBB (arrows). Abbreviations: OxA,
orexin-A; ChAT, choline acetyltransferase; VDBB, vertical limb of the diagonal
band. Scale bar represents approximately 100 µm
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3.3.4: Effects of intranasal [Ala11, D-Leu15]-OxB on c-Fos expression in cholinergic
neurons
Our work in young and aged animals utilized intranasal administration of the OxA
peptide to study its effects on cholinergic neurons (Calva et al. 2018; Calva and Fadel
2018); therefore, the receptor mechanisms by which intranasal orexin administration may
activate basal cholinergic neurons remained unresolved. Accordingly, we examined the
effects of intranasal [Ala11, D-Leu15]-OxB administration, a selective OX2 receptor
agonist, on c-Fos expression within cholinergic (ChAT+) neurons of the basal forebrain.
Ultimately, we discovered that intranasal [Ala11, D-Leu15]-OxB significantly increased cFos expression within cholinergic neurons of the medial septum compared to intranasal
saline administration (t12 = 2.704, p = 0.0192). Intranasal [Ala11, D-Leu15]-OxB
administration did not significantly alter activation of cholinergic neurons within any
other subdivision of the basal forebrain (data not shown).
3.3.5: Effects of intranasal orexin administration on c-Fos in GABAergic neurons
To analyze the effects of intranasal OxA on neuronal subpopulations in the
cortex, we stained cells for parvalbumin (PV), a marker for fast-spiking GABAergic
interneurons in the cortex (Hu et al. 2014). Indeed, analysis by one-way ANOVA
indicated a significant effect of treatment in the prelimbic cortex (PrLC; F3,28 = 14.44,
p<0.0001), the ventral orbital cortex (VOC; F3,27=7.120, p=0.0011), and in the claustrum
(Cl; F3,28=5.561, p=0.0040). Further analysis with Tukey’s multiple comparisons test
revealed that intranasal OxA decreased c-Fos expression in parvalbumin (PV+)
GABAergic interneurons of the prelimbic cortex (p=0.0118) of aged animals compared to
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treatment with intranasal saline. In young animals, Tukey’s multiple comparisons test
revealed that intranasal OxA decreased c-Fos expression in parvalbumin (PV+)
GABAergic interneurons of the prelimbic cortex (p=0.0038) and the ventral orbital cortex
(p=0.0007). Interestingly, PV+ GABAergic interneurons of the prelimbic cortex show
higher ‘basal’ activity under control treatment conditions in aged animals compared to
young animals (Figure 3.6). Furthermore, while ‘basal’ activation levels of PV+
GABAergic interneurons in the claustrum are not significantly different, under OxA
treatment conditions, aged animals exhibit significantly higher activity within this subset
of neurons compared to young animals treated with intranasal OxA (Figure 3.6).
Saline-Young
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Figure 3.6 Activation of PV+ GABAergic interneurons neurons in the cortex
by intranasal OxA administration. In aged animals, intranasal OxA
significantly decreased the number of active PV+ GABAergic interneurons
in the PrLC (n=8, saline; n=8, OxA). In young animals, intranasal OxA
significantly decreased the number of active PV+ GABAergic interneurons
in the PrLC, and VOC (n=8, saline; n=8, OxA). Data are represented as the
percentage of double-labeled (c-Fos/PV+) neurons relative to the total
number of PV+ neurons. #/$/*=p<.05, ^^=p<.01, ^^^=p<.001
62

Data are expressed as the percentage of PV positive neurons also expressing c-Fos
(Figure 3.6). Single-labeled and double-labeled PV neurons were counted within the
same 0.179mm x 0.179mm reticle area as c-Fos so that direct comparisons could be
established. Double–labeled PV neurons of the prelimbic cortex are depicted by arrows
showing blue-black immunoreactivity for c-Fos and brown immunoreactivity for PV
(Figures 3.7).

Figure 3.7 Representative photomicrograph depicting double-labeled parvalbumin
positive (PV+) GABAergic interneurons in the cortex. Activation of PV+
GABAergic interneurons in cortical brain regions after intranasal OxA
administration. Intranasal OxA significantly decreased the percentage of dual-labeled
PV neurons in the PrLC of young and aged animals. The bold black square on the
schematic indicates the approximate location within the PrLC where c-Fos/PV counts
and photomicrographs were obtained. The photomicrograph on the right shows
typical dual-label immunohistochemistry for c-Fos (blue/black) and PV (brown)
neurons within the PrLC (arrows). Abbreviations: PV, parvalbumin; OxA, orexin-A;
PrLC, prelimbic prefrontal cortex. Scale bar represents approximately 100 µm

Importantly, these observations indicate that intranasal OxA administration
decreases activation of fast-spiking PV+ GABAergic interneurons in the PFC. These cells
are the principal interneuron phenotype within the cortex and function to gate the firing
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of cortical pyramidal neurons (Kawaguchi and Kubota 1997; Kelsom and Lu 2013; Xu et
al. 2010; Hu et al. 2014; Sohal et al. 2009; Kim et al. 2015). While the mechanisms
driving this inhibition remain unknown, one possibility is through inhibition from basal
forebrain PV+ projection neurons that preferentially synapse onto PV+ cortical
interneurons (Henny and Jones 2008; Freund and Meskenaite 1992). In support of this
argument, we have data from aged animals that highlight the potential for this
mechanism. When analyzing the effects of intranasal OxA administration on cholinergic
neurons of the basal forebrain, we also investigated its effects in PV+ GABAergic
neurons of the basal forebrain of aged animals (Figure 3.8). Unfortunately, due to
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staining issues during immunohistochemistry, we were unable to achieve proper staining
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Figure 3.8 Activation of PV+ GABAergic neurons in
the basal forebrain after intranasal OxA administration
in aged animals. Intranasal OxA significantly increased
the percentage of dual-labeled PV+ neurons in the
horizontal limb of the diagonal band (HDBB) and in the
ventral pallidum/substantia innominata/nucleus basalis
(VP/SI/NBM) continuum of aged animals (n=8, saline;
n=8, OxA). Data are represented as the percentage of
double-labeled (c-Fos/PV+) neurons relative to the total
number of PV+ neurons. *=p<.05, **p<.01
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of PV+ neurons in the basal forebrain of young animals. Interestingly, intranasal OxA
selectively increases c-Fos expression within PV+ GABAergic neurons of the horizontal
limb of the diagonal band (HDBB; t13=2.580, p=0.02290) and the contiguous ventral
pallidum/substantia innominate/nucleus basalis region of the basal forebrain
(VP/SI/NBM; t13=4.175, p=0.0011). Activation of these neurons via orexins may
ultimately function to regulate cortical gamma band oscillations (Kim et al. 2015), a
putative electrophysiological correlate of attention and feature binding (Gray and Singer
1989; Tiitinen et al. 1997).
3.4: Discussion
These studies highlight that intranasal orexins selectively increase neuronal
activation in distinct cortical, basal forebrain, and brainstem regions. While intranasal
[Ala11, D-Leu15]-OxB selectively activates the piriform and agranular insular cortices,
intranasal OxA activates a broader range of cortical regions including the prelimbic and
ventral orbital cortices. These studies also demonstrate that intranasal OxA activates
basal forebrain cholinergic neurons in young and aged animals, which suggest a capacity
for intranasal OxA to modulate cholinergic neurotransmission across the lifespan.
3.4.1: Effects of intranasal orexin administration on cortical activation
Orexin neurons send widespread projections to the cortex that modulate various
aspects of cognition, especially those related to attentional function. Correspondingly,
intranasal [Ala11,D-Leu15]-OxB and intranasal OxA (Calva et al. 2018; Calva and Fadel
2018) increased c-Fos expression in the agranular insular cortex, a brain region that
facilitates interoceptive attention to an organism’s physiological status (Craig and Craig
2002; Avery et al. 2017; Hassanpour et al. 2017). Orexin’s actions in the insular cortex
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may help promote appropriate behavioral responses to homeostatic challenges, consistent
with orexin’s role as a physiological integrator. Indeed, previous evidence highlights that
modulation of orexin expression alters both behavioral and insular cortical cholinergic
responses to food-paired stimuli in food-restricted animals (Hagar et al. 2017).
Increased c-Fos expression, after intranasal OxA or [Ala11, D-Leu15]-OxB, was
also observed in the piriform cortex, suggesting that activation of this brain region is
primarily mediated through the OX2 receptor. This is consistent with OX receptor mRNA
expression patterns in the rat piriform cortex that indicate the selective presence of the
OX2 receptor (Marcus et al. 2001). The piriform cortex plays an important role in
olfactory discrimination (Stettler and Axel 2009; Bekkers and Suzuki 2013).
Interestingly, olfactory dysfunction occurs during aging and age-related cognitive
disorders (Enwere 2004; Mobley et al. 2014; Kovács 2004), and may serve as an early
predictor for AD (Sohrabi et al. 2012; Djordjevic et al. 2008; Hüttenbrink et al. 2013).
Orexin modulation of olfactory function has been demonstrated by studies that show
i.c.v. administration of OxA enhances olfactory sensitivity to odors (Prud’homme et al.
2009; Julliard et al. 2007). Together, these findings suggest that OX2 receptor-mediated
activation of the piriform cortex by OxA or [Ala11, D-Leu15]-OxB may serve to enhance
odor discrimination and olfactory function within the piriform cortex.
Orexin neurons also densely innervate the PFC where they modulate
neurotransmission related to attentional processing (Zajo et al. 2016; Fadel et al. 2005;
Huang et al. 2006; Vittoz and Berridge 2006). Though we observed a strong trend for
increased c-Fos expression in the prelimbic PFC after intranasal [Ala11, D-Leu15]-OxB
administration, our overall observations indicate that orexin-mediated enhancement of
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attentional function may primarily occur via the OX1 receptor. The extent to which
intranasal orexin administration modulates neurotransmission and cognitive function is
discussed in the upcoming chapters.
3.4.2: Effects of intranasal orexin administration on GABAergic neurons in the
basal forebrain
These observations indicate that intranasal OxA administration decreases
activation of fast-spiking PV+ GABAergic interneurons in the PFC of both young and
aged animals (Calva et al. 2018; Calva and Fadel 2018). These cells are the principal
interneuron phenotype within the cortex and function to gate the firing of cortical
pyramidal neurons (Kawaguchi and Kubota 1997; Kelsom and Lu 2013; Xu et al. 2010;
Hu et al. 2014; Sohal et al. 2009; Kim et al. 2015). While the mechanisms driving this
inhibition remain unknown, one possibility is through inhibition from basal forebrain
PV+ projection neurons that preferentially synapse onto PV+ cortical interneurons
(Henny and Jones 2008; Freund and Meskenaite 1992). Anatomical evidence suggests
that the large majority of these PV+ basal forebrain neurons are GABAergic (Gritti et al.
2003; Mckenna et al. 2013). Functionally, these PV+ basal forebrain projection neurons
regulate cortical gamma band oscillations (Kim et al. 2015), a putative
electrophysiological correlate of attention and feature binding (Gray and Singer 1989;
Tiitinen et al. 1997). Behavioral and electrophysiological evidence suggests that
activation of basal forebrain PV+ neurons is mediated primarily through the OX2 receptor
(Wu et al. 2002; Mieda et al. 2011). Given the prominent role of the orexin system in
modulating arousal/wakefulness (Sakurai 2002; Jones 2008), intranasal orexins may
ultimately regulate cortical activation through modulation of these PV+ neurons in the
basal forebrain.
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3.4.3: Effects of intranasal orexin administration on cholinergic neurons in the basal
forebrain
Orexin neurons are anatomically and functionally positioned to modulate
cholinergic neurotransmission. Specifically, orexin neurons modulate the basal forebrain
cholinergic system (BFCS), the primary source of cholinergic neurotransmission to the
cortex (Fadel and Burk 2010; Villano et al. 2017). Several studies illustrate interactions
between OxA and the basal forebrain. In particular, infusion of OxA directly into the
basal forebrain modulates cholinergic-dependent attentional processing and potently
increases cortical ACh release (Fadel et al. 2005; Zajo et al. 2016). Furthermore,
intranasal OxA activates cholinergic neurons of the ventral pallidum/substantia
innominata and vertical limb of the diagonal band of young animals (Calva et al. 2018)
and activates cholinergic neurons of the medial septum, vertical limb of the diagonal
band, and ventral pallidum/substantia innominate of aged animals. In contrast, intranasal
administration of [Ala11, D-Leu15]-OxB selectively activates cholinergic neurons of the
medial septum (Calva and Fadel 2018) . This pattern of activation is consistent with insitu evidence in rats that describes the selective presence of the OX2 receptor in the
medial septum (Marcus et al. 2001). As described above, intranasal OxA administration
also enhances activation of cholinergic neurons in the basal forebrain of aged animals,
indicating that intranasal OxA may be a viable therapeutic for treating age-related deficits
in neurotransmission. Accordingly, the effects of intranasal OxA administration on
cholinergic neurotransmission and cognitive function will be reviewed in the upcoming
chapters.
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CHAPTER 4
EFFECTS OF INTRANASAL OREXIN-A ADMINISTRATION ON PFC
NEUROTRANSMISSION AND ATTENTIONAL PERFORMANCE
4.1: Introduction
Collectively, the experiments presented in Chapter 3 demonstrate that intranasal
OxA administration increased c-Fos expression in many, but not all areas of cerebral
cortex, basal forebrain, and brainstem. The selective nature of OxA-elicited neuronal
activation was further demonstrated by a limited phenotypic analysis of these effects,
which revealed increased activation of basal forebrain cholinergic neurons but decreases
in Fos expression in GABAergic, PV+ interneurons in prelimbic and ventral orbital
cortices. Additionally, while intranasal [Ala11, D-Leu15]-OxB selectively activates the
piriform and agranular insular cortices, intranasal OxA activates a broader range of
cortical and subcortical brain regions. These studies also demonstrate that intranasal OxA
activates basal forebrain cholinergic neurons in young and aged animals, which suggest a
capacity for intranasal OxA to modulate cholinergic neurotransmission across the
lifespan. Our understanding of the effects of intranasal orexin administration on
neurotransmission and cognition will continue to evolve in the analysis of the following
studies using in-vivo microdialysis in the prefrontal cortex. Orexin neurons also densely
innervate the PFC where they modulate neurotransmission related to attentional
processing (Zajo et al. 2016; Fadel et al. 2005; Huang et al. 2006; Vittoz and Berridge
2006). Prior studies suggest that direct intrabasalis application of OxA increases cortical
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acetylcholine and enhances attentional function (Fadel et al. 2005; Zajo et al. 2016).
Combined with the evidence from our immunohistochemical studies, this suggests that
intranasal OxA may enhances attentional processing in the PFC via stimulated
acetylcholine release. Though we observed a strong trend for increased c-Fos expression
in the prelimbic PFC after intranasal [Ala11, D-Leu15]-OxB administration, our overall
observations indicate that orexin-mediated enhancement of attentional function may
primarily occur via the orexin-1 receptor. The purpose of these studies is to investigate
the extent to which intranasal orexin administration modulates neurotransmission and
cognitive function in young aged animals.
4.2: Methods
4.2.1: Stereotaxic surgery for implantation of guide cannulae
Under ketamine (90 mg/kg)/xylazine (2-10 mg/kg) anesthesia, animals used for
in-vivo microdialysis received a single guide cannula inserted into the prefrontal cortex
(PFC) at AP +2.8 mm, L ±0.5 mm, and DV -2.8 mm relative to bregma. Coordinates for
guide cannula implantation were obtained from the Paxinos and Watson rat brain atlas
(Paxinos and Watson 1998). The intracerebral guide cannula was anchored in place using
two to three skull screws and dental cement. Guide cannula placement was
counterbalanced so that left and right hemispheres were represented equally. During the
procedure, all animals were given a single dose of buprenorphine (0.01 mg/kg, s.c.) to
ease post-operative pain and were monitored until complete recovery.
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4.2.2: In-vivo microdialysis
In concordance with the immunohistochemistry experiments, animals used for the
in-vivo microdialysis experiments arrived in separate batches. Beginning 3 days after
cannula implantation, animals were habituated in microdialysis bowls for 3-4 days and
habituated with intranasal saline for 7 days. On microdialysis days, guide cannula stylets
were removed and substituted with a microdialysis probe that extended 2 mm past the
guide cannula. Probes were perfused at a 2 l/min flow rate with artificial cerebrospinal
fluid (aCSF, pH 7.4) containing: 150 mM NaCl, 3mM KCl, 1.7mM CaCl2, 0.9 mM
MgCl2, and 4.9 mM D-glucose. Neostigmine bromide (50 nM) was added to the aCSF to
increase recovery of acetylcholine in collected dialysates. Dialysate collection started
after a 3-hour discard period. Microdialysis sessions consisted of one hour (4 x 15-minute
collections) of baseline collections followed by intranasal vehicle (0.9% saline) or OxA
(100 µM), administered in a total volume of 50 µl in 12.5 l increments over a 2-minute
period. The individual performing intranasal administration was not blinded to treatment
conditions. Dialysate collection then continued for two hours (8 x 15-minute collections)
post-treatment. Upon collection, dialysates were stored at -80ºC until analysis using
HPLC. All animals underwent two separate microdialysis sessions with an off day inbetween and experiments were counterbalanced so that half of the animals received
vehicle during session one, while the other half received OxA in session one. The day
following the last microdialysis session, rats were euthanized and their brains processed
for future probe placement verification using an acetylcholinesterase (AChE) background
stain. Probe placement verification was performed after all HPLC samples were run for
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each respective animal. Any probe placement visualized outside the medial PFC excluded
the animal from the study.
4.2.3: High-performance liquid chromatography and chromatogram analysis
Each 30 µl dialysate was split prior to analysis by high performance liquid
chromatography with electrochemical detection (HPLC-ECD), with 20 µl analyzed for
ACh and 10 µl analyzed for glutamate. ACh was analyzed using an HTEC-510 HPLCECD (EicomUSA; San Diego, CA, USA). Briefly, 20 l of each dialysate was loaded
into the AC-GEL separation column (2.0 ID x 150mm; EicomUSA) maintained at a
constant 33ºC in combination with mobile phase (pH 8.5) containing 49.4 mM potassium
bicarbonate (KHCO3), 134.3 M ethylenediaminetetraacetic acid disodium (EDTA-2Na),
and 1.23 mM sodium 1- decanesulfonate. After analyte separation, post-column
derivatization of ACh was attained through use of an AC-ENYM II enzyme reactor (1.0
ID x 4 mm; EicomUSA) containing acetylcholinesterase and choline oxidase, which
generates hydrogen peroxide (H2O2) proportional to the amount of ACh present. The
H2O2 is further broken down and detected on a platinum working electrode with an
applied potential of +450 mV. The amount of ACh in each sample was measured by
comparison with a three-point external standard curve with values predicted to be in
range of the collected dialysates. The limit of detection for this analysis was
approximately 5 fmol/injection.
Glutamate levels in brain dialysates were analyzed using a CC-32 HPLC-ECD
(BASi; West Lafayette, IN, USA) with modifications. First, 10 l of each dialysate was
loaded into the GU-GEL separation column (4.6 ID x 150mm; EicomUSA) in
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conjunction with a mobile phase (pH 7.2) containing 60 mM ammonium chlorideammonium hydroxide, 134.3 nM EDTA-2Na, and 686 M
hexadecyltrimethylammonium bromide. After separation, post-column derivatization of
glutamate was attained using an E-ENZ enzyme reactor (3.0 ID x 40 mm; EicomUSA)
containing glutamate oxidase, which generates H2O2 proportional to the amount of
glutamate present. The H2O2 is further broken down and detected on a 3.0 mm glassy
carbon electrode (BASi) coated with a horseradish peroxidase osmium polyvinylpyridine
solution (0 mV applied potential). The amount of glutamate in each dialysate was
measured by comparison with a three-point standard curve using external standards
expected to be in range of the collected dialysates. The limit of detection for this method
was approximately 3 fmol/injection.
4.2.4: Attentional set-shifting paradigm
In rodents, the attentional set-shifting task takes each animal through a series of
increasingly difficult tasks in which they must dig in small containers to locate a food
reward (Birrell and Brown 2000). The specific procedures for our attentional set-shifting
task were adapted and modified from previous studies using similar methods (Birrell and
Brown 2000; Lapiz-Bluhm et al. 2008; Snyder et al. 2012; Barense 2002; Liston et al.
2006; Bissonette et al. 2013). Young and aged FBN/F1 rats were approximately 3-4
months and 26-28 months, respectively, upon arrival to the animal facility. Upon arrival,
both young and aged animals were assigned to receive intranasal administration of either
vehicle (50L of 0.9% saline) or OxA (50L of a 100M solution; Enzo Life Sciences,
Farmingdale, NY, USA). All animals were acclimatized to individual housing for at least
4 days prior to the start of any behavioral procedures. For approximately one week prior
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to testing, each rat was maintained on a food restricted diet of approximately 14g per day,
such that by testing day, each rat weighed approximately 80-90% of their free-feeding
body weight. Each animal received several days of gentle handling and habituation to
intranasal saline administration prior to the testing day. All behavioral experiments were
conducted during the light portion of the cycle, between 07:00 and 19:00 h. Our testing
apparatus was a custom-built black rectangular Plexiglas arena with inner dimensions of
75L x 40W x 30H (Snyder et al. 2012). The testing arena contained a black Plexiglas
removable divider to separate one-third of the arena from the remaining two-thirds of the
arena. This smaller portion of the arena served as the starting box for each rat and as a
holding area between each trial. Each trial began after lifting the removable divider,
allowing the rats to access the remainder of the arena. The larger portion of the divided
arena contained an irremovable and opaque Plexiglas panel to split the arena into two
sections. These two sections served as the holding area for the digging bowls. A visual
representation of the testing arena is shown in Figure 2.3. The digging pots used for these
experiments were small plastic containers (internal rim diameter 7 cm; depth 3.5 cm).
Each digging pot was distinguished by a pair of cues along two different stimulus
dimensions: (1) the digging medium held in each pot and (2) an odor applied to the rim of
each pot. The relevant/irrelevant dimensions and the positive/negative cue pairs for each
stage of the task are shown in Table 2.1. To mark each digging pot with an odor,
approximately 50 µl of extract was initially applied to the inner rim of the pot. Each
digging pot receives only one odor and a different pot is used for each combination. No
specific odors or media are necessary for this experiment; however, odor and media
pairings should be different enough for each animal to discriminate between (i.e. do not
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pair lemon & lime or wood beads & plastic beads). The reward used for these
experiments, buried approximately 2 cm beneath the surface of each medium, was a
‘bacon softie’ broken into small pieces. For each trial, a small amount of reward was
ground and applied to the surface of both pots to ensure that each animal was digging
correctly based upon the positive cues rather than by smelling the food reward. After the
animals were food restricted for at least 5 days, the 3-day behavioral procedure was
conducted in the following manner:
Habituation Day (Day 1): before receiving their daily ration of standard rat chow,
rats were trained to dig reliably in each pot for a food reward (bacon softie). First, two
unscented plastic digging pots are placed into the home cage and baited. Each animal is
first allowed to retrieve the reward from both pots without being covered. If the animal
has not retrieved both food rewards after 5 minutes, the animal is given a ‘time-out’
period of 30 minutes and subsequently retried. Ultimately, each animal is required to dig
for the food reward in each pot in 3 trials of 5 minutes each, with the food reward
covered with an increasing amount of sawdust during each exposure. After the animal is
digging reliably, it is placed in the testing arena and habituated to digging in the same
manner described above.
Training Day (Day 2): before receiving their daily ration of standard rat chow,
rats are trained on a simple discrimination (SD) task to a criterion of six consecutive
correct trials. Each trial during the discrimination tasks was timed for up to 10 minutes. If
the animal did not retrieve the reward after 10 minutes, a non-digging response, or
‘error’, was recorded. Any animal with six- consecutive errors was subsequently
excluded from further experimentation. All rats start by learning to associate the food
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reward with the positive odor cue (the starting media is sawdust in both digging pots). In
these experiments, rosemary and orange were used as the odors. After six consecutive
correct trials, the animals were then trained to discriminate between two different media
to achieve a reward. For these experiments, wood chips and gauze were used as the
media. All animals were trained with these odors and media with the positive and
negative cues randomly chosen for each animal. Importantly, the training stimuli were
never used on testing days to ensure that animals were not remembering odor or media
pairings.
Testing Day (Day 3): before receiving their daily ration of standard rat chow, each
animal was tested on a series of five increasingly difficult discrimination tasks (Table
2.1). Again, the criterion used to proceed to the next stage of the experiment was six
consecutive correct digging responses. The first stage, like training day, was a simple
discrimination (SD) task. For the SD stage, half of the animals were required to
discriminate between two odors (i.e. strawberry vs. cinnamon) to retrieve a reward while
the other half were required to discriminate between two media (i.e. paper vs. felt) to
retrieve a reward. Only one of the digging pots (i.e. the positive cue pot) contained the
food reward. The second stage was a compound discrimination task (CD), where the
irrelevant stimuli from the other dimension were introduced, but the animal was still
required to discriminate between the two original stimuli from the SD stage. The third
stage was an intradimensional shift (IDS), where all new stimuli were used, however, the
task-relevant dimension was unchanged. For example, if the starting relevant dimension
was odor, the IDS stage would introduce new odors and media, however, the relevant
discriminatory dimension would still be odor. At this point in the task, the animal was
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given its predetermined treatment (i.e. intranasal saline or intranasal OxA). This
timepoint for treatment was based upon the in-vivo microdialysis studies where the effect
of intranasal OxA on PFC acetylcholine efflux lasted approximately 30-60 minutes.
Because the ASST experiment lasts 2-3 hours for each animal, intranasal OxA was given
just before the reversal learning stage (REV) of the task to allow for optimal assessment
of each treatment on prefrontal cortical function. The fourth stage of the task was a
reversal learning (REV) stage, where the relevant dimension remains the same, however,
the previously negative cue is now the positive cue. The fifth and final stage was an
extradimensional attentional shift (EDS). In this stage, all new stimuli are introduced, but
now the relevant dimension is changed. For example, if the starting relevant dimension
was odor, the EDS stage would introduce new odors and media, and the relevant
discriminatory dimension would change to media. For each animal, assignment to a
positive or negative cue, relevant starting dimension, and left-right positioning of the pots
within the arena were determined randomly in advance.
4.2.5: Statistics and data analysis
For the in-vivo microdialysis data, baseline neurotransmitter efflux was obtained
during the first four sample collections (i.e. timepoints 1-4) and averaged to yield mean
basal efflux. For each sample analyzed, a raw value was obtained and expressed as
pmol/20L for ACh and mol/l0L for glutamate. The graphed in-vivo microdialysis
data are expressed as a percentage of the average baseline to account for individual
variation in basal neurotransmitter efflux. Data were analyzed using two-way repeatedmeasure ANOVAs (GraphPad Prism 8) with treatment as a within-subjects variable, age
as a between-subjects variable, and time as a repeated measure. Significant interactions

77

and main effects of treatment (i.e., OxA or saline) or age were probed with Tukey
multiple comparisons tests. A significance cutoff level of p<0.05 was used for all
analyses.
For the attentional set-shifting experiments, trials to reach criterion (6 consecutive
correct trials) was recorded for each rat. Because intranasal saline or intranasal OxA was
given just before the REV stage of the ASST experiment, the first three stages and the
final two stages were assessed differently. For the first 3 stages of the task (i.e. SD, CD,
IDS; before treatment), the groups were collapsed to assess differences in task
performance between young and aged animals. These results were analyzed using twotailed unpaired t-tests. For the final 2 stages of the task (i.e. REV, EDS; after treatment),
each treatment group was analyzed on its own using ordinary one-way ANOVAs
followed by Holm-Sidak multiple comparisons to determine significant differences
between the treatment groups. Data were represented as total number of trials to reach
criterion (y-axis) for each stage (x-axis). A significance cutoff level of p<0.05 was used
for all analyses.
4.3: Results
4.3.1: Intranasal orexin-A: PFC glutamate efflux in young and aged rats
After observing increased c-Fos expression in the prelimbic prefrontal cortex
(PFC) of both young and aged rats, we then investigated the effects of intranasal OxA on
PFC neurotransmission using microdialysis. When analyzing the results of intranasal
OxA administration on glutamate efflux in the PFC, intranasal OxA resulted in a
significant TIME x TREATMENT interaction (F33,330=1.560, p=0.0289). There was no
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significant main effect of TIME (F2.029,60.88=0.2592, p=0.7757) or TREATMENT
(F3,30=1.771, p=30.1740). Multiple comparisons indicated that the young saline and aged
saline treated groups had significantly different glutamate efflux at timepoints 11 and 12
with the young saline group exhibiting higher glutamate efflux. Furthermore, young
intranasal OxA treated animals also exhibited significantly higher glutamate efflux at
timepoints 11 and 12 compared to aged saline treated animals. Interestingly, glutamate
efflux in intranasal OxA treated aged animals was not significantly different from young
OxA or young saline treatment groups which may indicate that aged animals, under
control conditions, have deficits in glutamate neurotransmission or gliotransmission.
Multiple comparisons yielded no other significant effects (Figure 4.1).
4.3.2: Intranasal orexin-A: PFC acetylcholine efflux in young and aged rats
When analyzing the results of intranasal OxA administration on acetylcholine
efflux in the PFC, intranasal OxA significantly increased ACh efflux in the PFC as
indicated by a significant main effect of TIME (F11,352=17.06, p<0.001), a significant
main effect of TREATMENT (F3,32=10.21, p<0.0001), and a significant TIME x
TREATMENT interaction (F33,352=5.025, p<0.0001). Further analysis with Tukey
multiple comparisons indicated that young animals treated with intranasal OxA had
significantly increased ACh efflux compared to young animals treated with intranasal
saline. The significant increase in ACh persisted from collections five through nine
(approximately 1 hour and 15 minutes). Aged animals treated with intranasal OxA also
exhibited an increase in PFC ACh release that was significantly different from aged
matched controls. In the aged animals that received intranasal OxA, the significant
increase in PFC ACh efflux lasted from collections six through seven (approximately 30
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Figure 4.1 PFC glutamate efflux after intranasal OxA administration in young and
aged animals. Statistical analyses for PFC glutamate efflux revealed a significant
TIME x TREATMENT interaction (p=0.0289). Tukey multiple comparisons:
Aged animals (n=7, saline; n=7 OxA) and Young animals (n=10, saline; n=10,
OxA). Young saline and aged saline treated groups had significantly different
glutamate efflux at timepoints 11 and 12 with the young saline group exhibiting
higher glutamate efflux. The young intranasal orexin-A treated animals also
exhibited significantly higher glutamate efflux at timepoints 11 and 12 compared
to aged saline treated animals. */$=p<0.05
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minutes). In addition to having a shorter time course of intranasal OxA elicited ACh
efflux, peak efflux in aged animals was also significantly lower compared to young
animals treated with intranasal OxA. Young animals treated with intranasal OxA had a
peak ACh efflux that was approximately 233% of baseline while aged animals treated
with intranasal OxA had a peak ACh efflux at around 186% of baseline (Figure 4.2).
Probe placement verification via acetylcholinesterase background staining stain revealed
that the 2-mm active membrane portion of the dialysis probe was centered in the
prelimbic portion of the PFC with a small degree of overlap dorsally into the anterior
cingulate cortex or ventrally into infralimbic portion of the prefrontal cortex (Figure 2.2,
Chapter 2)
4.3.3: Attentional set-shifting: effects of intranasal orexin-A on attentional function
Proper cholinergic neurotransmission in the PFC is crucial for sustained attention
(Himmelheber et al. 1997; Dalley et al. 2001; Sarter et al. 2005) and decreased ACh within
the PFC represents a neurochemical correlate of age-related attentional dysfunction (Herzog
et al. 2003; Burk et al. 2002; Muir 1997). Attentional function is modulated by the orexin
system through its action on converging glutamatergic and cholinergic inputs that ultimately
arrive at the PFC (Huang et al. 2006; Lambe et al. 2005; Fadel et al. 2005). Prior work has
previously demonstrated a capacity for OxA to increase cortical ACh levels and attentional
processing, even among rats with lesions to the BFCS inputs to the PFC (Fadel and Burk
2010; Zajo et al. 2016). These studies, combined with our studies highlighting increased PFC
efflux of ACh after intranasal OxA administration, suggest that intranasal OxA may
ameliorate age-related deficits in attention. To test the hypothesis that intranasal OxA
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Figure 4.2 PFC acetylcholine efflux after intranasal OxA administration in young
and aged animals. Intranasal OxA significantly increased acetylcholine (ACh) efflux
within the prefrontal cortex (PFC) relative to treatment with intranasal saline.
Statistical analyses for PFC ACh efflux revealed a significant effect of treatment
(p<0.0001) and a TIME x TREATMENT interaction (p<.0001). Tukey multiple
comparisons: In young animals (n=10, saline; n=10 OxA), intranasal OxA
significantly increased PFC ACh efflux from timepoints 5-9. In aged animals (n=8,
saline; n=8, OxA), intranasal OxA significantly increased PFC ACh efflux from
timepoints 6-7. Young intranasal OxA treated animals had a significantly higher
peak efflux of ACh in the PFC compared to aged animals treated with intranasal
OxA ****= p<0.0001, ###=p<0.001, **=p<0.01, $=p<0.05
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improves aged related impairments in attentional performance, I used the attentional set
shifting paradigm along with intranasal administration of saline or OxA to determine the
therapeutic potential of OxA (Figure 4.3). I hypothesized that I would see age-related
impairments on the EDS stage of the task as aged animals have previously been reported to
be impaired on this stage (Barense 2002). I also hypothesized that intranasal OxA would
improve age-related attentional deficits on the EDS stage of the task through increased
acetylcholine release in the PFC (Calva et al. 2018; Calva and Fadel 2018). Two-tailed
unpaired t-tests on the first three stages of the task (before treatment) indicated that there
were no significant differences in performance between young and aged animals. One-way
ANOVAs on the final two stages of the task revealed a significant effect between treatment
groups on the EDS stage (F3,24=3.444, p=0.0326). Holm-Sidak multiple comparisons
revealed that aged animals treated with saline were significantly impaired on the EDS stage
of the task compared to young animals treated with saline (p=0.0227). While intranasal OxA
did not significantly improve performance in aged animals compared to aged animals treated
with saline, performance of the aged-OxA group on the EDS stage was not significantly
different from young saline or young OxA treated animals. A one-way ANOVA also
revealed a significant effect between treatment groups on the REV stage of the ASST task
(F3,24=3.120, p=0.0448). Holm-Sidak multiple comparisons revealed that young animals
treated with OxA performed significantly worse on the REV stage compared to young
animals treated with saline (p=0.0409).
4.4: Discussion
The collective microdialysis results demonstrate that intranasal OxA
administration rapidly and significantly increases ACh and glutamate within the PFC, an
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Figure 4.3 Performance of young and aged animals treated with
intranasal saline or intranasal OxA in the attentional set-shifting task.
Young animals treated with intranasal OxA (n=7) were significantly
impaired on the REV stage of the task compared with young animals
treated with intranasal saline (n=7). Aged animals treated with saline
(n=6) were significantly impaired on the EDS stage of the task compared
with young animals treated with intranasal saline. Intranasal OxA
treatment in aged animals (n=8) did not significantly improve
performance on the EDS stage or REV stage of the task.
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area important for multiple aspects of executive and cognitive function. Thus, in this
rodent model, intranasal OxA proved effective at reaching the brain and modulating the
activity of prefrontal cortical neurotransmitter systems that modulate attentional function.
4.4.1: Mechanistic considerations for neuronal activation and neurotransmission
The effects of intranasal OxA administration on c-Fos are corroborated by our
effects seen through in-vivo microdialysis. In summary, intranasal OxA significantly
increased both acetylcholine efflux within the PFC. The Ox1R and Ox2R are both
expressed in the basal forebrain (Marcus et al. 2001). While direct receptor mechanisms
involving intranasal OxA administration cannot be determined from these studies alone,
prior studies indicate that our effects may primarily be an Ox1R-mediated phenomenon.
For example, intrabasalis administration of OxA elicits a greater response on
somatosensory cortical ACh release than OxB (Dong et al. 2006). Studies from our lab
corroborate this finding as the specific Ox1R antagonist SB-334867 block stimulated
ACh release during feeding (Frederick-Duus et al. 2007). Furthermore, the results from
the intranasal [Ala11, D-Leu15]-OxB studies suggested that activation of cholinergic
neurons in the basal forebrain was limited to the medial septum, which is not a major
source of cholinergic input to the prefrontal cortex (Mesulam et al. 1983a). Still, it is
possible that the Ox2R plays a large role in the effects mediated by intranasal OxA
administration as previous work using in vitro electrophysiology has reported that OxB is
as effective as OxA at exciting basal forebrain cholinergic neurons (Eggermann et al.
2001). Importantly, the large increases in ACh efflux in young rats (233% of baseline)
and aged rats (186% of baseline) that we observed translate to previous work showing
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that high levels of ACh in the hippocampus and neocortex set the dynamics for increased
attention (Hasselmo and McGaughy 2004).
Changes to glutamatergic transmission in the PFC after intranasal OxA
administration in young and aged animals were less clear. Statistical analyses indicated
that young saline and aged saline treated groups had significantly different glutamate
efflux at timepoints 11 and 12 with the young saline group exhibiting higher glutamate
efflux. Interestingly, PFC glutamate efflux in aged animals treated with intranasal OxA
did not differ significantly from the young OxA or young saline treatment groups which
may indicate that aged animals, under control (i.e. saline treatment) conditions, have
dysfunction in glutamatergic neurotransmission or gliotransmission. Mechanistically,
these effects can arise from a variety of sources. In brain microdialysis, a large majority
of the amino acid neurotransmitters sampled under basal conditions are derived from
reverse transporter activity or from glial cells (Timmerman and Westerink 1997;
Westerink 1995). Intranasal OxA could also be acting locally within the PFC as orexin
receptors are expressed in this brain region (Hervieu et al. 2001; Marcus et al. 2001) and
OxA has been shown stimulate presynaptic glutamate release in the PFC (Lambe et al.
2007). Visualization of (5(6)-FAM-(Glu¹)-Hypocretin-1) in the PFC via fluorescence
supports a direct effect of intranasal OxA on PFC pyramidal neurons. Indirectly,
increases in PFC glutamate efflux could also stem from excitation of glutamatergic
thalamocortical synapses originating from the paraventricular nucleus (Lambe et al.
2005; Huang et al. 2006) or from orexin neurons that co-express glutamate (Rosin et al.
2003; Blanco-Centurion et al. 2018; Schöne and Burdakov 2012). The latter possibility
seems unlikely, however, as there were no differences in c-Fos expression in orexin
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labeled neurons between intranasal vehicle and intranasal OxA treated animals (data not
shown).
4.4.2: Therapeutic potential of intranasal OxA for attentional dysfunction
Intranasal OxA in young and aged animals elicited an interesting set of behavioral
responses in the attentional set-shifting task. Aged Long-Evans rats have previously been
shown to exhibit impaired performance on the EDS stage of the ASST experiment (Barense
2002), a behavioral correlate of mPFC dysfunction (Birrell and Brown 2000). Indeed, in our
ASST paradigm, aged animals treated with intranasal saline were impaired on the EDS stage
compared with young animals treated with saline. Altogether, this suggests that aged animals
display impaired PFC mediated attentional performance compared to young animals and that
these deficits are extended across multiple strains (Barense 2002). Furthermore, while
intranasal OxA did not significantly improve performance in aged animals compared to aged
saline treated animals, EDS performance of the aged-OxA group was not significantly
different from young-saline or young OxA treated animals. Together, this would suggest that
intranasal OxA returns PFC mediated attentional function in aged animals to levels on par
with their younger counterparts. Indeed, this putative effect is supported by the following
evidence: (1) intranasal OxA increases PFC ACh release (Calva et al. 2018) and (2) direct
OxA application into the basal forebrain enhances cholinergic dependent attentional
processing (Fadel et al. 2005; Zajo et al. 2016). Finally, intranasal OxA administration
impaired the performance of young animals on the REV stage of the ASST task compared to
young animals treated with intranasal saline. Ultimately, this suggests that acute
administration of OxA to cognitively intact younger subjects does not enhance attentional
performance and may significantly impair cognitive performance overall.

87

CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
5.1: Conclusions
The OxA neuropeptide exerts equal affinity for both orexin receptor subtypes;
therefore, the neurochemical and behavioral observations surrounding this neuropeptide
cannot be attributed to one specific receptor. In addition, because of caveats surrounding
the use of G-protein-coupled receptor agonists (e.g., differences in penetrance, unknown
brain concentrations with systemic administration, etc.) it is difficult to say definitively
what the receptor mechanisms are that mediate single-dose in-vivo responses. However,
the available evidence suggests that our effects following intranasal orexin are primarily
mediated via the OX1 receptor, particularly those involving the basal forebrain
cholinergic system. For example, systemic or intrabasalis administration of the specific
OX1 receptor antagonist SB-334867 attenuates ACh release that is induced during
feeding (Frederick-Duus et al. 2007). Additionally, OxA administration into the basal
forebrain results in greater ACh release in the somatosensory cortex compared to OxB
(Dong et al. 2006). Furthermore, the observations described above indicate that intranasal
administration of the OX2 receptor agonist [Ala11, D-Leu15]-OxB results in the activation
of fewer brain regions than intranasal OxA. Nevertheless, the OX2 receptor likely plays
an important role in various aspects of orexin mediated neurotransmission. For example,
we observed that medial septal cholinergic neurons were selectively activated by [Ala11,
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D-Leu15]-OxB. Furthermore, previous evidence indicates that orexins likely mediate
activation of BF PV+ neurons through the OX2 receptor (Wu et al. 2002; Mieda et al.
2011). Intriguingly, in-vitro evidence indicates that BF cholinergic neurons potently
excite BF PV+ and other GABAergic neurons (Yang et al. 2014), suggesting that
cholinergic and GABAergic systems in the BF work in tandem to modulate cortical
activity. Because intranasal OxA and [Ala11, D-Leu15]-OxB affect distinct cholinergic
and GABAergic systems, this evidence indicates that intranasal orexins facilitate
cognition, in part, through coordinated activation of cholinergic and GABAergic
neurotransmission in the basal forebrain. These putative mechanisms that underlie the
behavioral and neurochemical correlates of intranasal orexin administration are outlined
in a summary figure (Figure 5.1).
5.1.1: Therapeutic implications of intranasal orexin administration
Accumulating behavioral evidence from both animals and humans suggests that
intranasal OxA administration may be useful in treating a variety of cognitive disorders.
Recent rodent studies have demonstrated that intranasal OxA administration increases
locomotion and food intake (Dhuria et al. 2016). Additionally, intranasal OxA
administration in sleep deprived rhesus macaque monkeys improves performance in a
short-term memory task and alters local cerebral glucose metabolism (Deadwyler et al.
2007). Of clinical significance, intranasal OxA administration in patients with narcolepsy
has been shown to decrease the number of spontaneous wake-REM sleep transitions,
improve deficits in olfactory acuity, and enhance divided attention (Baier et al., 2011,
2008; S L Weinhold et al., 2014). The subtle similarities in the cognitive deficits between
narcolepsy and some forms of age-related cognitive decline, especially deficits in
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Figure 5.1 Putative mechanisms underlying intranasal orexin entry and action within
the brain. Orexins administered via the intranasal route are hypothesized to enter the
brain via two main mechanisms: 1) diffusion across the olfactory epithelium into
olfactory and rostral brain areas and 2) extra-axonal diffusion along trigeminal
sensory pathways into brainstem regions. After accessing the CNS, our data suggests
that orexins activate basal forebrain cholinergic neurons via the orexin-1 or orexin-2
receptor. Excitation of these neurons by orexins ultimately increases acetylcholine
efflux within the prefrontal cortex, a putative neurochemical correlate of attention.
We also observed that intranasal orexin-A administration increases neuronal
activation of excitatory pyramidal neurons and decreases neuronal activation of
inhibitory parvalbumin-positive GABAergic interneurons within the prefrontal cortex.
This dichotomy may ultimately arise from orexin-2 receptor-mediated excitation of
parvalbumin-positive GABAergic neurons within the basal forebrain. These
inhibitory projections neurons of the basal forebrain preferentially synapse onto
cortical GABAergic interneurons. Finally, we observed that intranasal orexin-A
administration can activate brainstem neurons of the pedunculopontine tegmental
nucleus, which may also modulate activity within the basal forebrain and/or cortex.
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attention, hint at the involvement of the orexin system (Hüttenbrink et al. 2013; Perry and
Hodges 1999a; Sarter and Turchi 2002; Wesson et al. 2010). Indeed, aged animal models
are associated with a reduction in orexin neurons and/or neuropeptide expression (Terao
et al. 2002; Porkka-Heiskanen et al. 2004; Kessler et al. 2011). Furthermore, a reduced
number of orexin neurons has also been observed, post-mortem, in patients with AD and
dementia with Lewy bodies (Fronczek et al. 2012; Kasanuki et al. 2014).
The neuronal and pharmacological mechanisms underlying the effect of orexins
on cognitive function remain to be fully elucidated. Advancements may include peptide
or vehicle modifications that enhance brain penetrance, such as inclusion of cyclodextrin
compounds to promote bioavailability of intranasally-administered proteins and peptides
(Meredith et al. 2015). Development of novel ligands such as the non-peptide OX2
receptor agonist YNT-185, which has recently shown promise in murine narcolepsy
models (Irukayama-Tomobe et al. 2017; Takenoshita et al. 2018), will also facilitate
advancements in this field. Furthermore, it will be important to more fully examine and
clarify potential negative effects of intranasal orexin on disease processes such as
amyloid plaque formation (Kang et al. 2009; Liguori 2017) prior to clinical
implementation. Nonetheless, as described above, intranasal orexin administration
rapidly enters the brain and targets brain regions and neurotransmitter systems that
mediate proper cognitive functioning. Ultimately these studies provide mechanistic
evidence for the therapeutic potential of intranasal orexin administration in treating agerelated cognitive dysfunction.

91

5.2: Future Directions
Several future avenues of research can be taken to further enhance the
understanding of the results presented here. While these experiments provide a
therapeutic context for acute intranasal orexin administration in treating age-related
cognitive dysfunction, further work utilizing chronic administration will be needed to
determine if long-term dosing enhances or is detrimental to cognitive function.
Furthermore, dose-response studies using intranasal orexin would help determine the
doses needed for optimal cognitive enhancement in aged animals. Dose-response studies
would also help clarify the possible detrimental effects of intranasal OxA in cognitively
intact younger animals. Importantly, both the young and aged animals demonstrate an
ability to perform the attentional set-shifting task. This is highlighted by the fact that
neither the young or aged animal groups exhibit behavioral deficits on the first three
stages of the behavioral task which, classically, are less cognitively demanding compared
with the reversal learning and extradimensional shift. The fact that aged animals take
more trials to complete difficult stages of this behavioral task indicate that this paradigm
may be useful in testing other investigative treatments for age-related cognitive
dysfunction. Ultimately, the gold-standard for determining therapeutic efficacy, or lack
thereof, lies within dose-response studies with acute and chronic dosing regiments.
Unfortunately, limited studies have assessed multiple doses of orexin-A, particularly
intranasal OxA, in modulating behavioral responses. Nonetheless, preliminary studies
using a radiolabeled OxA peptide indicate that intranasal administration of 10 nmol and
100 nmol OxA reach various regions of the brain in a dose-dependent manner (Dhuria et
al. 2016). Interestingly, recent work has suggested that higher i.p doses of OxA in rats
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(40 µg/kg) attenuates prepulse inhibition (PPI) in non-sleep deprived rats, while lower i.p
doses of OxA (10 µg/kg) ameliorates impairments in PPI in sleep-deprived rats (Öz et al.
2018). These data highlight the importance of optimizing the appropriate dose in
behavioral experiments and to the critical need for testing during all phases of the
sleep/wake cycle. Apart from OxA, the newly developed YNT-185 compound, an orexin2 receptor selective agonist, has also shown promise in dose-response studies.
Administration of YNT-185 to wild-type mice via three separate modes of delivery
(i.c.v., i.p., i.v) all resulted in dose-dependent enhancement of wakefulness during the
light phase. Furthermore, YNT-185, in a dose-dependent manner, was also able to
alleviate spontaneous transitions from wakefulness to REM sleep in multiple models of
mouse narcolepsy. Of additional importance, no desensitization to the YNT-185
compound was observed in the narcoleptic mouse models (Irukayama-Tomobe et al.
2017). Together, these collective studies highlight the importance for utilizing both
chronic administration paradigms as well as experimental designs that account for dose
optimization for intranasal OxA administration.
While the interactions between orexins and the systems that support proper
cognition are multifarious, these inextricable associations and results may ultimately be
explained via an inverted U-shaped curve that shifts across the lifespan. For example, if
orexin levels are deficient, as may be the case in aged animals (Kessler et al. 2011), a
lower dose of intranasal OxA may be sufficient to ameliorate cognitive deficits,
conceivably from a compensatory upregulation of orexin receptors. Conversely, in
younger animals with an intact orexin system, intranasal orexin-A may ultimately perturb
normal cognitive function, perhaps through an overabundance of excitatory
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neurotransmission within the PFC. Ultimately, dose-response studies using intranasal
OxA and other orexin receptor targets will elucidate the nature of these inverted Ushaped curves and how they might shift during aging.
Finally, these experiments should, of course, be repeated in female rats to
determine if there are sex differences in the ability of intranasal OxA to treat age-related
cognitive dysfunction. Assessing these sex differences will be particularly important due
to the new body of evidence highlighting sex differences in orexin mediated responses to
stress and cognitive flexibility (Grafe et al. 2017) .
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